[Guardian] Calabar -The United States of America and European countries may with effect from tomorrow, stop issuance of visas to prominent Nigerian elite and politicians.
Reported by allAfrica.com 2 hours ago.
Nigeria: U.S., Europe May Stop Giving Visa to Nigerian Elite, Politicians
↧
↧
Euronext announces the launch of its cash tender offer for Oslo Børs VPS
*CONTACT - Media:*
* * *CONTACT - Investor Relations:*
Amsterdam +31.20.721.4488 Brussels +32.2.620.15.50 +33.1.70.48.24.17
Dublin
Paris +353.1.617.4266
+33.1.70.48.24.45 Lisbon +351.210.600.614
The distribution of the offer document and the making of the offer may in certain jurisdictions be restricted by law, including without limitation in Canada, Australia and Japan. Accordingly, the offer is not made and does not constitute an offer or solicitation in these jurisdictions, or in any jurisdiction or to any person where the making or acceptance of the offer or solicitation would be in violation of the laws or regulations of such jurisdiction.
*EURONEXT ANNOUNCES THE LAUNCH OF ITS CASH TENDER OFFER FOR OSLO BØRS VPS*
*Amsterdam, Brussels, Dublin, Lisbon, London and Paris - 14 January 2019 -* Euronext, the leading pan-European exchange, today published the offer document for its previously announced all-cash tender offer to acquire all issued and outstanding shares of Oslo Børs VPS Holding ASA ("Oslo Børs VPS") for NOK 6.24 billion (€625m^[1]). The offer document is available at: www.euronext.com:
· The offer price is *NOK 145 per share*, representing a 32 % premium on Oslo Børs VPS's closing price on 17 December 2018^[2] and 34 % on Oslo Børs VPS's 3-month volume-weighted average share price. Each accepting shareholder will also receive an interest payment on the offer price equal to 6 % per annum, from the date of acceptance until fulfilment of the conditions of the offer.
· The *acceptance period of the tender offer commences today, will expire at 17:30 Central European Time on 11 February 2019*, and can be extended if appropriate. Euronext has already secured support for the offer from Oslo Børs VPS shareholders representing 50.5% of the total number of outstanding shares through irrevocable binding pre-commitments to tender shares in the context of the offer, and share purchases.
· The offer is *subject to fulfilment or waiver of certain conditions*, including but not limited to minimum acceptance level of at least 50.01 % of Oslo Børs VPS outstanding shares (including shares already held by Euronext), regulatory approvals, short confirmatory due diligence, a favourable vote from a majority of Euronext shareholders and completion of the transaction before 31 August 2019.
If its offer is accepted, Euronext, already managing the national stock exchanges of five European countries and the Portuguese CSD, will be fully committed to *the further development of Oslo Børs VPS, both its stock exchange and the central securities depository (CSD, known as 'VPS'), as well as the broader Norwegian financial ecosystem*. In this context, Euronext's strategic ambition relies on a strong commitment to:
· *increase the prominence of Oslo Børs VPS's* trading business, by leveraging Euronext capabilities to position it as the *key capital markets hub in the Nordic region*, capitalising on its leading position in the energy, shipping and seafood sector, and as the launchpad for expansion in the Nordic region;
· offer Oslo Børs VPS's issuers and investors the benefits of access to the *largest liquidity pool in Europe*; *build a truly pan-European market data offering *by combining Oslo Børs VPS's data and audience with that of Euronext;
· make Oslo Børs VPS *the Group's center of excellence for all Euronext activities in commodities*;
· *promote market integrity and inclusion within Euronext's open and decentralised model*, including, among other initiatives, the invitation for the Oslo Børs VPS CEO to join the Managing Board of Euronext as country CEO for Norway with Group-wide responsibilities for commodities, and for a leading figure of the Norwegian financial ecosystem to join the Supervisory Board of Euronext, subject to required approvals;
· *enhance Oslo Børs VPS's technology and innovation capabilities*, notably through the roll-out of Euronext's state-of-the-art proprietary Optiq^TM trading technology;
· *secure the position of VPS, the national CSD, *through commitment to technology investments, operational independence and continued local supervision and regulation;
· invest in *educational programmes dedicated to supporting SMEs and family businesses and to develop corporate social responsibility products *for the benefit of* financing the real economy*;
· leverage the depth of Euronext's suite of services for the benefit of Norwegian investors and issuers, by *providing access to global FX markets for investors and to a full range of service tools for issuers and investors.*
Stéphane Boujnah, Chief Executive Officer and Chairman of the Managing Board of Euronext, said:
"In a rapidly evolving and increasingly competitive global market, Euronext strongly believes that Oslo Børs VPS would improve its competitive positioning, further increase its relevance to the Norwegian financial ecosystem and reinforce its strong existing international listing franchise by joining forces with Euronext, the leading pan-European market infrastructure. If the offer is accepted, Oslo Børs VPS would benefit from the largest European liquidity pool, Euronext's cutting edge technology and innovation capabilities, and access to new asset classes, tools and markets. Oslo Børs VPS would maintain its identity and integrity within Euronext's decentralised model, while the CSD VPS would keep its operational independence to serve the Norwegian investor community, in an integrated framework of governance and supervision. The combination would be a major milestone towards Euronext's vision of building a consistent pan-European marketplace offering best-in-class capital markets services."
For more details on the strategic ambition of Euronext, please refer to paragraph 2.1 and 2.2 of the Offer document, available on www.euronext.com.
*A conference call and a webcast will be held today at 9.00am CET (Paris time) / 8.00am UK time:*
To connect to the conference call, please dial:
France number: +33 1 72727403
UK number: +44 2071943759
Belgium number: +32 24035816
Netherlands number: +31 20709511
Ireland number: +35 315060451
United States number: +1 6467224916
Norway number: +47 23500272
Portugal number: +351 210609110
*PIN CODE: 63431841#*
*Media *
Pauline Bucaille: +33 1 70 48 24 41; mediateam@euronext.com
*Analysts & investors*
Aurélie Cohen: * *+33 1 70 48 24 17; ir@euronext.com
*About Eurone**xt*
Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.4 trillion in market capitalisation as of end December 2018, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 IndexSM and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.
For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).
*Disclaimer*
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided "as is" without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication should be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.
This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.
© 2018, Euronext N.V. - All rights reserved.
The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of these personal data, Euronext will comply with its obligations under the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR. In accordance with the applicable legislation you have a right to access your personal data and a right to the rectification, erasure, restriction of processing, data portability or to object to the processing of your personal data. You may also submit a complaint to the competent data privacy authority. For any request regarding the processing of your data, please use our data subject request form or email our Data Protection Officer at dpo@euronext.com. Your personal data will be retained as long as necessary for the Purpose and will be accessible only to the extent necessary for this specific Purpose.
*Important Notice*
THE OFFER IS BEING MADE TO SHAREHOLDERS OF OSLO BORS VPS RESIDENT IN THE UNITED STATES IN RELIANCE ON THE TIER I EXEMPTION PURSUANT TO RULE 14d-1(c) UNDER THE U.S. SECURITIES EXCHANGE OF 1934, AS AMENDED (THE "EXCHANGE ACT").
THE OFFEROR RESERVES THE RIGHT TO ACQUIRE OR AGREE TO ACQUIRE SHARES OR RIGHTS IN SHARES OUTSIDE THE OFFER DURING THE ACCEPTANCE PERIOD IN ACCORDANCE WITH APPLICABLE LAW AND REGULATIONS AND THE PROVISIONS OF THE EXEMPTION PROVIDED UNDER RULE 14e-5(b)(10) UNDER THE EXCHANGE ACT. ANY OF THE PURCHASES REFERRED TO IN THIS PARAGRAPH MAY OCCUR EITHER IN THE OPEN MARKET AT PREVAILING PRICES OR IN PRIVATE TRANSACTIONS AT NEGOTIATED PRICES. INFORMATION ABOUT SUCH PURCHASES WILL BE DISCLOSED AS AND IF REQUIRED BY APPLICABLE SECURITIES LAWS.
THE OFFER IS BEING MADE FOR THE SECURITIES OF A NORWEGIAN COMPANY AND APPLICABLE DISCLOSURE REQUIREMENTS MAY BE DIFFERENT FROM U.S. DISCLOSURE REQUIREMENTS. IN ADDITION, SHAREHOLDERS RESIDENT IN THE UNITED STATES SHOULD BE AWARE THAT THE OFFER DOCUMENT HAS BEEN PREPARED IN A FORMAT AND STYLE, WHICH DIFFER FROM THE U.S. FORMAT AND STYLE. NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE OFFER OR PASSED UPON THE ADEQUACY OR COMPLETENESS OF THIS NOTICE OR ANY DOCUMENTATION RELATING TO THE OFFER. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.
FURTHERMORE, THE PAYMENT AND SETTLEMENT PROCEDURE WITH RESPECT TO THE OFFER DIFFERS FROM U.S. PAYMENT AND SETTLEMENT PROCEDURES, PARTICULARLY WITH REGARD TO THE DATE OF PAYMENT OF CONSIDERATION. Completion of the Offer is also subject to the fulfilment and/or waiver of certain conditions, which may result in the Shares of accepting Shareholders being blocked by the Receiving Agent for a period up to the Long-Stop Date (31 August 2019). Acceptance of the Offer is irrevocable and accepting Shareholders will have no withdrawal rights with respect to their Shares.
THIS ANNOUNCEMENT, AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES, IS AVAILABLE ONLY TO (I) PERSONS WHO ARE OUTSIDE THE UNITED KINGDOM, (II) INVESTMENT PROFESSIONALS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER"), (III) HIGH NET WORTH COMPANIES FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, (IV) PERSONS WITHIN THE SCOPE OF ARTICLE 43 OF THE ORDER, OR (V) ANY OTHER PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE MADE UNDER THE ORDER (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS ANNOUNCEMENT MAY NOT BE ACTED OR RELIED ON IN THE UNITED KINGDOM BY ANYONE WHO IS NOT A RELEVANT PERSON.
^[1]Based on an exchange rate of EUR 1.00 = NOK 9.97 as of December 23, 2018.
^[2]Which is the last trading day before Euronext submitted its offer to certain Oslo Børs VPS shareholders.
*Attachment*
· 20190114Euronext_OsloBorsVPS_Offer.pdf Reported by GlobeNewswire 2 hours ago.
* * *CONTACT - Investor Relations:*
Amsterdam +31.20.721.4488 Brussels +32.2.620.15.50 +33.1.70.48.24.17
Dublin
Paris +353.1.617.4266
+33.1.70.48.24.45 Lisbon +351.210.600.614
The distribution of the offer document and the making of the offer may in certain jurisdictions be restricted by law, including without limitation in Canada, Australia and Japan. Accordingly, the offer is not made and does not constitute an offer or solicitation in these jurisdictions, or in any jurisdiction or to any person where the making or acceptance of the offer or solicitation would be in violation of the laws or regulations of such jurisdiction.
*EURONEXT ANNOUNCES THE LAUNCH OF ITS CASH TENDER OFFER FOR OSLO BØRS VPS*
*Amsterdam, Brussels, Dublin, Lisbon, London and Paris - 14 January 2019 -* Euronext, the leading pan-European exchange, today published the offer document for its previously announced all-cash tender offer to acquire all issued and outstanding shares of Oslo Børs VPS Holding ASA ("Oslo Børs VPS") for NOK 6.24 billion (€625m^[1]). The offer document is available at: www.euronext.com:
· The offer price is *NOK 145 per share*, representing a 32 % premium on Oslo Børs VPS's closing price on 17 December 2018^[2] and 34 % on Oslo Børs VPS's 3-month volume-weighted average share price. Each accepting shareholder will also receive an interest payment on the offer price equal to 6 % per annum, from the date of acceptance until fulfilment of the conditions of the offer.
· The *acceptance period of the tender offer commences today, will expire at 17:30 Central European Time on 11 February 2019*, and can be extended if appropriate. Euronext has already secured support for the offer from Oslo Børs VPS shareholders representing 50.5% of the total number of outstanding shares through irrevocable binding pre-commitments to tender shares in the context of the offer, and share purchases.
· The offer is *subject to fulfilment or waiver of certain conditions*, including but not limited to minimum acceptance level of at least 50.01 % of Oslo Børs VPS outstanding shares (including shares already held by Euronext), regulatory approvals, short confirmatory due diligence, a favourable vote from a majority of Euronext shareholders and completion of the transaction before 31 August 2019.
If its offer is accepted, Euronext, already managing the national stock exchanges of five European countries and the Portuguese CSD, will be fully committed to *the further development of Oslo Børs VPS, both its stock exchange and the central securities depository (CSD, known as 'VPS'), as well as the broader Norwegian financial ecosystem*. In this context, Euronext's strategic ambition relies on a strong commitment to:
· *increase the prominence of Oslo Børs VPS's* trading business, by leveraging Euronext capabilities to position it as the *key capital markets hub in the Nordic region*, capitalising on its leading position in the energy, shipping and seafood sector, and as the launchpad for expansion in the Nordic region;
· offer Oslo Børs VPS's issuers and investors the benefits of access to the *largest liquidity pool in Europe*; *build a truly pan-European market data offering *by combining Oslo Børs VPS's data and audience with that of Euronext;
· make Oslo Børs VPS *the Group's center of excellence for all Euronext activities in commodities*;
· *promote market integrity and inclusion within Euronext's open and decentralised model*, including, among other initiatives, the invitation for the Oslo Børs VPS CEO to join the Managing Board of Euronext as country CEO for Norway with Group-wide responsibilities for commodities, and for a leading figure of the Norwegian financial ecosystem to join the Supervisory Board of Euronext, subject to required approvals;
· *enhance Oslo Børs VPS's technology and innovation capabilities*, notably through the roll-out of Euronext's state-of-the-art proprietary Optiq^TM trading technology;
· *secure the position of VPS, the national CSD, *through commitment to technology investments, operational independence and continued local supervision and regulation;
· invest in *educational programmes dedicated to supporting SMEs and family businesses and to develop corporate social responsibility products *for the benefit of* financing the real economy*;
· leverage the depth of Euronext's suite of services for the benefit of Norwegian investors and issuers, by *providing access to global FX markets for investors and to a full range of service tools for issuers and investors.*
Stéphane Boujnah, Chief Executive Officer and Chairman of the Managing Board of Euronext, said:
"In a rapidly evolving and increasingly competitive global market, Euronext strongly believes that Oslo Børs VPS would improve its competitive positioning, further increase its relevance to the Norwegian financial ecosystem and reinforce its strong existing international listing franchise by joining forces with Euronext, the leading pan-European market infrastructure. If the offer is accepted, Oslo Børs VPS would benefit from the largest European liquidity pool, Euronext's cutting edge technology and innovation capabilities, and access to new asset classes, tools and markets. Oslo Børs VPS would maintain its identity and integrity within Euronext's decentralised model, while the CSD VPS would keep its operational independence to serve the Norwegian investor community, in an integrated framework of governance and supervision. The combination would be a major milestone towards Euronext's vision of building a consistent pan-European marketplace offering best-in-class capital markets services."
For more details on the strategic ambition of Euronext, please refer to paragraph 2.1 and 2.2 of the Offer document, available on www.euronext.com.
*A conference call and a webcast will be held today at 9.00am CET (Paris time) / 8.00am UK time:*
To connect to the conference call, please dial:
France number: +33 1 72727403
UK number: +44 2071943759
Belgium number: +32 24035816
Netherlands number: +31 20709511
Ireland number: +35 315060451
United States number: +1 6467224916
Norway number: +47 23500272
Portugal number: +351 210609110
*PIN CODE: 63431841#*
*Media *
Pauline Bucaille: +33 1 70 48 24 41; mediateam@euronext.com
*Analysts & investors*
Aurélie Cohen: * *+33 1 70 48 24 17; ir@euronext.com
*About Eurone**xt*
Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.4 trillion in market capitalisation as of end December 2018, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 IndexSM and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.
For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).
*Disclaimer*
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided "as is" without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication should be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.
This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.
© 2018, Euronext N.V. - All rights reserved.
The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of these personal data, Euronext will comply with its obligations under the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR. In accordance with the applicable legislation you have a right to access your personal data and a right to the rectification, erasure, restriction of processing, data portability or to object to the processing of your personal data. You may also submit a complaint to the competent data privacy authority. For any request regarding the processing of your data, please use our data subject request form or email our Data Protection Officer at dpo@euronext.com. Your personal data will be retained as long as necessary for the Purpose and will be accessible only to the extent necessary for this specific Purpose.
*Important Notice*
THE OFFER IS BEING MADE TO SHAREHOLDERS OF OSLO BORS VPS RESIDENT IN THE UNITED STATES IN RELIANCE ON THE TIER I EXEMPTION PURSUANT TO RULE 14d-1(c) UNDER THE U.S. SECURITIES EXCHANGE OF 1934, AS AMENDED (THE "EXCHANGE ACT").
THE OFFEROR RESERVES THE RIGHT TO ACQUIRE OR AGREE TO ACQUIRE SHARES OR RIGHTS IN SHARES OUTSIDE THE OFFER DURING THE ACCEPTANCE PERIOD IN ACCORDANCE WITH APPLICABLE LAW AND REGULATIONS AND THE PROVISIONS OF THE EXEMPTION PROVIDED UNDER RULE 14e-5(b)(10) UNDER THE EXCHANGE ACT. ANY OF THE PURCHASES REFERRED TO IN THIS PARAGRAPH MAY OCCUR EITHER IN THE OPEN MARKET AT PREVAILING PRICES OR IN PRIVATE TRANSACTIONS AT NEGOTIATED PRICES. INFORMATION ABOUT SUCH PURCHASES WILL BE DISCLOSED AS AND IF REQUIRED BY APPLICABLE SECURITIES LAWS.
THE OFFER IS BEING MADE FOR THE SECURITIES OF A NORWEGIAN COMPANY AND APPLICABLE DISCLOSURE REQUIREMENTS MAY BE DIFFERENT FROM U.S. DISCLOSURE REQUIREMENTS. IN ADDITION, SHAREHOLDERS RESIDENT IN THE UNITED STATES SHOULD BE AWARE THAT THE OFFER DOCUMENT HAS BEEN PREPARED IN A FORMAT AND STYLE, WHICH DIFFER FROM THE U.S. FORMAT AND STYLE. NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE OFFER OR PASSED UPON THE ADEQUACY OR COMPLETENESS OF THIS NOTICE OR ANY DOCUMENTATION RELATING TO THE OFFER. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.
FURTHERMORE, THE PAYMENT AND SETTLEMENT PROCEDURE WITH RESPECT TO THE OFFER DIFFERS FROM U.S. PAYMENT AND SETTLEMENT PROCEDURES, PARTICULARLY WITH REGARD TO THE DATE OF PAYMENT OF CONSIDERATION. Completion of the Offer is also subject to the fulfilment and/or waiver of certain conditions, which may result in the Shares of accepting Shareholders being blocked by the Receiving Agent for a period up to the Long-Stop Date (31 August 2019). Acceptance of the Offer is irrevocable and accepting Shareholders will have no withdrawal rights with respect to their Shares.
THIS ANNOUNCEMENT, AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES, IS AVAILABLE ONLY TO (I) PERSONS WHO ARE OUTSIDE THE UNITED KINGDOM, (II) INVESTMENT PROFESSIONALS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER"), (III) HIGH NET WORTH COMPANIES FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, (IV) PERSONS WITHIN THE SCOPE OF ARTICLE 43 OF THE ORDER, OR (V) ANY OTHER PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE MADE UNDER THE ORDER (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS ANNOUNCEMENT MAY NOT BE ACTED OR RELIED ON IN THE UNITED KINGDOM BY ANYONE WHO IS NOT A RELEVANT PERSON.
^[1]Based on an exchange rate of EUR 1.00 = NOK 9.97 as of December 23, 2018.
^[2]Which is the last trading day before Euronext submitted its offer to certain Oslo Børs VPS shareholders.
*Attachment*
· 20190114Euronext_OsloBorsVPS_Offer.pdf Reported by GlobeNewswire 2 hours ago.
↧
Global Mango Puree Market Will Reach USD 2,120 Million By 2024: Zion Market Research
According to the report, the global mango puree market was valued at around USD 950 million in 2017 and is expected to reach approximately USD 2,120 million by 2024, at a CAGR of slightly above 7.7% between 2018 and 2024.
New York, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Mango Puree Market by Nature (Organic and Conventional), by Packaging (Can, Pouch, P.E.T Jars, and Bottles), and by Distribution Channel (Departmental Stores, Convenience Stores, Specialty Stores, Online Retail, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024’’*. According to the report, the global mango puree market was valued at around USD 950 million in 2017 and is expected to reach approximately USD 2,120 million by 2024, at a CAGR of slightly above 7.7% between 2018 and 2024.
Mango puree is prepared from selected varieties of fresh mango fruit. The preparation process includes cutting, de-stoning, refining, and packing. In case of aseptic products, the pulp is sterilized and packed in aseptic bags. The refined pulp is packed in cans, hermetically sealed, and retorted. The frozen pulp is pasteurized and deep-frozen in plate freezers. This process ensures that the natural flavor and aroma of the fruit is retained in the final products.
*Browse through 105 Tables & 28 Figures spread over 110 Pages and in-depth TOC on “Global Mango Puree Market: Industry Type, Size, Share, Trends and Forecast, 2017—2024”.*
*Request Free Sample Report of Global Mango Puree Market Report @* https://www.zionmarketresearch.com/sample/mango-puree-market
The major factor that is likely to support the growth of the mango puree market is the increased product demand from the beverage industry in the upcoming years. Various large-scale food producers have introduced products based on mango puree into the market. Various companies, such as Starbucks, McDonald's, etc., largely use fruit purees in their smoothies. These smoothies are in large demand among the consumers, which is likely to positively leverage the mango puree market in the future. Moreover, increasing consumption of flavored yogurt in various regions across the globe is anticipated to further support the growth of this market. The organic mango puree is in higher demand by consumers due to growing awareness regarding the usage of organic products. Alternatively, increasing product applications in various segments, such as ice cream and baby food, is expected to create many growth opportunities for the key players operating in the global mango puree market in the future.
The global mango puree market can be segmented based on nature, packaging, and distribution channel. By nature, the market is segmented into organic and conventional. Organic mango purre segment is expected to dominate the global mango puree market, owing to the wide product availability in various parts of the world. The packaging segment is divided into cans, pouches, P.E.T jars, and bottles. By distribution channel, the market is segmented into departmental stores, convenience stores, specialty stores, online retail, and others. Pouches are expected to dominate the global mango puree market due to their flexibility and ability to keep the product fresh and best to store liquid and semi-liquid products.
*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/mango-puree-market
By region, this global market includes Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region held a significant share of the global mango puree market in terms of volume in the year 2017. This is due to the huge demand for organic fruit juice across the region. India is one of the biggest exporters of mangoes in the entire region. Moreover, a large number of key players are present in this region that is fuelling various product developments, which, in turn, is likely to drive this regional market in the future.
North America is likely to witness a substantial rate of growth in the global mango puree market and register the highest rate in the years to come. The region is experiencing steady growth in various end-use industries and developed countries, such as Canada and the U.S., are likely to hold a large share of the global mango puree market. Moreover, the growing consumer demand for organic mango puree in the region is another major factor that is likely to support the growth of this regional market in the upcoming years.
Browse the full *“Mango Puree Market by Nature (Organic and Conventional), by Packaging (Can, Pouch, P.E.T Jars, and Bottles), and by Distribution Channel (Departmental Stores, Convenience Stores, Specialty Stores, Online Retail, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”* Report at https://www.zionmarketresearch.com/report/mango-puree-market
The European region is likely to witness a sluggish rate of growth in the mango puree market over the forecast time period. The region is experiencing considerable demand for mango puree due to increased consumer preference for buying natural or organic products. Moreover, there is tremendous growth witnessed in the beverage industry, which is also anticipated to support the growth of the region’s mango puree market over the estimated timeline.
*Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/mango-puree-market
Some major players operating in the global mango puree market include Varadaraja Foods Private Limited, Tree Top Inc., Dohler GmbH, Galla Foods, Mother India Farms, AGRANA Group, Superior Foods, Inc., and 7D Mangoes, among others.
*Request customized copy of report @ *https://www.zionmarketresearch.com/custom/3526
*This report segments the global mango puree market into:*
*Mango Puree Market: Nature Analysis*
· Organic
· Conventional
*Mango Puree Market: Packaging Analysis*
· Can
· Pouch
· P.E.T Jars
· Bottles
*Mango Puree Market: Distribution Channel Analysis*
· Departmental Stores
· Convenience Stores
· Specialty Stores
· Online Retail
· Others
*Mango Puree Market: Regional Analysis*
· North America
· The U.S.
· Europe
· UK
· France
· Germany
· Asia Pacific
· China
· Japan
· India
· Latin America
· Brazil
· The Middle East and Africa
*Related Reports:*
· *Liquid Breakfast Products Market: *https://www.zionmarketresearch.com/report/liquid-breakfast-products-market
· *Chlorella Market:* https://www.zionmarketresearch.com/report/chlorella-market
· *Garlic Extract Market:* https://www.zionmarketresearch.com/report/garlic-extract-market
· *Fish Oil Market:* https://www.zionmarketresearch.com/report/fish-oil-market
· *Chocolate Market:* https://www.zionmarketresearch.com/report/chocolate-market
*About Us:*
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research
*Blog:* http://usindustrynews.com | http://europeindustrynews.com | http://zmrresearchnews.us | http://zmrnewsanalysis.com
*Contact Us:*
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com
*Website:* https://www.zionmarketresearch.com
*Blog:* http://zmrblog.com Reported by GlobeNewswire 1 hour ago.
New York, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Mango Puree Market by Nature (Organic and Conventional), by Packaging (Can, Pouch, P.E.T Jars, and Bottles), and by Distribution Channel (Departmental Stores, Convenience Stores, Specialty Stores, Online Retail, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024’’*. According to the report, the global mango puree market was valued at around USD 950 million in 2017 and is expected to reach approximately USD 2,120 million by 2024, at a CAGR of slightly above 7.7% between 2018 and 2024.
Mango puree is prepared from selected varieties of fresh mango fruit. The preparation process includes cutting, de-stoning, refining, and packing. In case of aseptic products, the pulp is sterilized and packed in aseptic bags. The refined pulp is packed in cans, hermetically sealed, and retorted. The frozen pulp is pasteurized and deep-frozen in plate freezers. This process ensures that the natural flavor and aroma of the fruit is retained in the final products.
*Browse through 105 Tables & 28 Figures spread over 110 Pages and in-depth TOC on “Global Mango Puree Market: Industry Type, Size, Share, Trends and Forecast, 2017—2024”.*
*Request Free Sample Report of Global Mango Puree Market Report @* https://www.zionmarketresearch.com/sample/mango-puree-market
The major factor that is likely to support the growth of the mango puree market is the increased product demand from the beverage industry in the upcoming years. Various large-scale food producers have introduced products based on mango puree into the market. Various companies, such as Starbucks, McDonald's, etc., largely use fruit purees in their smoothies. These smoothies are in large demand among the consumers, which is likely to positively leverage the mango puree market in the future. Moreover, increasing consumption of flavored yogurt in various regions across the globe is anticipated to further support the growth of this market. The organic mango puree is in higher demand by consumers due to growing awareness regarding the usage of organic products. Alternatively, increasing product applications in various segments, such as ice cream and baby food, is expected to create many growth opportunities for the key players operating in the global mango puree market in the future.
The global mango puree market can be segmented based on nature, packaging, and distribution channel. By nature, the market is segmented into organic and conventional. Organic mango purre segment is expected to dominate the global mango puree market, owing to the wide product availability in various parts of the world. The packaging segment is divided into cans, pouches, P.E.T jars, and bottles. By distribution channel, the market is segmented into departmental stores, convenience stores, specialty stores, online retail, and others. Pouches are expected to dominate the global mango puree market due to their flexibility and ability to keep the product fresh and best to store liquid and semi-liquid products.
*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/mango-puree-market
By region, this global market includes Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region held a significant share of the global mango puree market in terms of volume in the year 2017. This is due to the huge demand for organic fruit juice across the region. India is one of the biggest exporters of mangoes in the entire region. Moreover, a large number of key players are present in this region that is fuelling various product developments, which, in turn, is likely to drive this regional market in the future.
North America is likely to witness a substantial rate of growth in the global mango puree market and register the highest rate in the years to come. The region is experiencing steady growth in various end-use industries and developed countries, such as Canada and the U.S., are likely to hold a large share of the global mango puree market. Moreover, the growing consumer demand for organic mango puree in the region is another major factor that is likely to support the growth of this regional market in the upcoming years.
Browse the full *“Mango Puree Market by Nature (Organic and Conventional), by Packaging (Can, Pouch, P.E.T Jars, and Bottles), and by Distribution Channel (Departmental Stores, Convenience Stores, Specialty Stores, Online Retail, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”* Report at https://www.zionmarketresearch.com/report/mango-puree-market
The European region is likely to witness a sluggish rate of growth in the mango puree market over the forecast time period. The region is experiencing considerable demand for mango puree due to increased consumer preference for buying natural or organic products. Moreover, there is tremendous growth witnessed in the beverage industry, which is also anticipated to support the growth of the region’s mango puree market over the estimated timeline.
*Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/mango-puree-market
Some major players operating in the global mango puree market include Varadaraja Foods Private Limited, Tree Top Inc., Dohler GmbH, Galla Foods, Mother India Farms, AGRANA Group, Superior Foods, Inc., and 7D Mangoes, among others.
*Request customized copy of report @ *https://www.zionmarketresearch.com/custom/3526
*This report segments the global mango puree market into:*
*Mango Puree Market: Nature Analysis*
· Organic
· Conventional
*Mango Puree Market: Packaging Analysis*
· Can
· Pouch
· P.E.T Jars
· Bottles
*Mango Puree Market: Distribution Channel Analysis*
· Departmental Stores
· Convenience Stores
· Specialty Stores
· Online Retail
· Others
*Mango Puree Market: Regional Analysis*
· North America
· The U.S.
· Europe
· UK
· France
· Germany
· Asia Pacific
· China
· Japan
· India
· Latin America
· Brazil
· The Middle East and Africa
*Related Reports:*
· *Liquid Breakfast Products Market: *https://www.zionmarketresearch.com/report/liquid-breakfast-products-market
· *Chlorella Market:* https://www.zionmarketresearch.com/report/chlorella-market
· *Garlic Extract Market:* https://www.zionmarketresearch.com/report/garlic-extract-market
· *Fish Oil Market:* https://www.zionmarketresearch.com/report/fish-oil-market
· *Chocolate Market:* https://www.zionmarketresearch.com/report/chocolate-market
*About Us:*
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research
*Blog:* http://usindustrynews.com | http://europeindustrynews.com | http://zmrresearchnews.us | http://zmrnewsanalysis.com
*Contact Us:*
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com
*Website:* https://www.zionmarketresearch.com
*Blog:* http://zmrblog.com Reported by GlobeNewswire 1 hour ago.
↧
Automotive Bearing Market Projected to Reach $53.3 Billion by 2025: P&S Intelligence
*Automotive Bearing Market by Bearing Type (Roller Bearing [Tapered Roller Bearing, Cylindrical Roller Bearing, Spherical Roller Bearing, Needle Roller Bearing, Thrust Roller Bearing], Ball Bearing [Deep-Groove Ball Bearing, Angular Contact Ball Bearing, Thrust Ball Bearing, Self-Aligning Ball Bearing], Plain Bearing), by Vehicle Type (Two-Wheeler, Passenger Car, Commercial Vehicle, Electric Vehicle [Two-Wheeler, Passenger Car, Commercial Vehicle]), by Sales Channel (OEM, OES, IAM), by Material (Metal Polymer, Solid Polymer, Fiber-Reinforced Composite, Others), by Application (Transmission, Axle, Wheel End, Engine, Others), by Geography (U.S., Mexico, Canada, Germany, U.K., France, Italy, Spain, Netherlands, Norway, China, Japan, South Korea, India, Australia, U.A.E., Brazil) – Global Market Size, Share, Development, Growth, and Demand Forecast, 2013–2025*NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- According to the market research report published by P&S Intelligence, automotive bearing market is projected to reach $53.3 billion by 2025. The market growth is primarily driven by growing automotive industry coupled with increasing focus toward vehicle weight reduction. Several manufacturers are focusing to improve vehicle efficiency by reducing weight of the vehicle. For this, they are focusing on lightweight bearings employing high durability and stiffness. Besides this, the manufacturers are also using low torque and enhanced forging techniques in bearing production. Thus, the increased focus on reducing the weight of the vehicle is resulting in growing adoption rate of advanced bearings, which sequentially, is propelling the growth of the market.
*Request to get the sample pages of the report: https://www.psmarketresearch.com/market-analysis/automotive-bearing-market/report-sample*
On the basis of bearing type, the automotive bearing market has been categorized into ball bearing, roller bearing, and plain bearing. Among these, ball bearing is estimated to hold the largest market share in 2018 with around 50% of the total market share in terms of volume. This is due to the high usage of ball bearings in passenger cars and two-wheelers. However, during the forecast period, the market share of ball bearing is anticipated to decrease, while the share of roller bearing is expected to increase, owing to the growth in manufacturing and sales of heavy-duty vehicles.
Based on vehicle type, the automotive bearing market has been categorized into two-wheeler, passenger car, commercial vehicle, and electric vehicle. Of these, the market for automotive bearings in electric vehicle showcased the fastest growth, in terms of volume, during the historical period. Increased government support in form of subsidies and regulations, and public acceptance of electric vehicles drove the demand for these vehicles, which in turn, boosted the market growth, globally.
*Browse report overview with 198 tables and 97 figures spread through 237 pages and detailed TOC on "Automotive Bearing Market" at: https://www.psmarketresearch.com/market-analysis/automotive-bearing-market*
Of all the sales channel, which comprise original equipment manufacturer (OEM), original equipment supplier (OES), and independent aftermarket (IAM), the market for automotive bearings in the OEM category is expected to witness the fastest growth, during the forecast period. Bearing manufacturers are rapidly developing and improving their platforms, products, and related services, and increasing product development capabilities to deliver better solutions to their customers. These increase the bearings demand in the OEM category, which in turn, boost the growth of the automotive bearing market.
Geographically, the APAC region is estimated to hold the largest share in the global automotive bearing market, accounting for more than 45% sales volume in 2018. Among the countries, China is expected to remain the market leader for automotive bearings, due to the rising regional demand for the automotive vehicles. Exports of low-end and small-sized bearings significantly drive the automotive bearing industry in China.
*Make enquiry before buying the report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=automotive-bearing-market*
Companies in the automotive bearing industry are actively participating in mergers and acquisitions, in order to expand their product portfolio and gain more share in the market. For instance, in 2018, the Timken Company acquired Cone Drive Operations Inc., a precision drives and gears manufacturer; and ABC Bearings Ltd., an Indian bearing manufacturing company, to enlarge its portfolio and strengthen its export capabilities to serve the automotive bearing market.
Some of the major players operating in the automotive bearing market are JTEKT Corporation, MINEBEA MITSUMI Inc., NSK Ltd., NTN Corporation, Schaeffler AG, The Timken Company, AB SKF, RBC Bearings Inc., NACHI-FUJIKOSHI CORP., C&U Group Ltd., and others.
*More Reports by P&S Intelligence*
*Automotive Window and Sealing Systems Market*
Urbanization, particularly in developing economies of the world, such as China and India, has been on the rise. There has been significant improvement in the lifestyle and living standard of people in these economies in the recent past, resulting in an increase in their purchasing power. This has allowed consumers in these countries to spend a significant share of their income on the purchase of vehicles for personal use, which, in turn, has positively affected the sales of automotive window and sealing systems.
*https://www.psmarketresearch.com/market-analysis/automotive-window-and-sealing-systems-market*
*Armored Vehicles Market*
Europe accounted for the largest region in the global armored vehicles market, where Germany contributed to the largest revenue. The U.S. was the major market for armored vehicles in North America, whereas Japan contributed to the largest revenue in Asia-Pacific region. Saudi Arabia generated the largest revenue for armored vehicles in the Middle East and Africa; whereas Brazil is expected to lead the global market for armored vehicles during the forecast period.
*https://www.psmarketresearch.com/market-analysis/armored-vehicles-market*
*About P&S Intelligence*
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
*Contact:*
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
*Connect with us: *LinkedIn* | *Twitter* | *Google +* | *Facebook Reported by GlobeNewswire 1 hour ago.
*Request to get the sample pages of the report: https://www.psmarketresearch.com/market-analysis/automotive-bearing-market/report-sample*
On the basis of bearing type, the automotive bearing market has been categorized into ball bearing, roller bearing, and plain bearing. Among these, ball bearing is estimated to hold the largest market share in 2018 with around 50% of the total market share in terms of volume. This is due to the high usage of ball bearings in passenger cars and two-wheelers. However, during the forecast period, the market share of ball bearing is anticipated to decrease, while the share of roller bearing is expected to increase, owing to the growth in manufacturing and sales of heavy-duty vehicles.
Based on vehicle type, the automotive bearing market has been categorized into two-wheeler, passenger car, commercial vehicle, and electric vehicle. Of these, the market for automotive bearings in electric vehicle showcased the fastest growth, in terms of volume, during the historical period. Increased government support in form of subsidies and regulations, and public acceptance of electric vehicles drove the demand for these vehicles, which in turn, boosted the market growth, globally.
*Browse report overview with 198 tables and 97 figures spread through 237 pages and detailed TOC on "Automotive Bearing Market" at: https://www.psmarketresearch.com/market-analysis/automotive-bearing-market*
Of all the sales channel, which comprise original equipment manufacturer (OEM), original equipment supplier (OES), and independent aftermarket (IAM), the market for automotive bearings in the OEM category is expected to witness the fastest growth, during the forecast period. Bearing manufacturers are rapidly developing and improving their platforms, products, and related services, and increasing product development capabilities to deliver better solutions to their customers. These increase the bearings demand in the OEM category, which in turn, boost the growth of the automotive bearing market.
Geographically, the APAC region is estimated to hold the largest share in the global automotive bearing market, accounting for more than 45% sales volume in 2018. Among the countries, China is expected to remain the market leader for automotive bearings, due to the rising regional demand for the automotive vehicles. Exports of low-end and small-sized bearings significantly drive the automotive bearing industry in China.
*Make enquiry before buying the report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=automotive-bearing-market*
Companies in the automotive bearing industry are actively participating in mergers and acquisitions, in order to expand their product portfolio and gain more share in the market. For instance, in 2018, the Timken Company acquired Cone Drive Operations Inc., a precision drives and gears manufacturer; and ABC Bearings Ltd., an Indian bearing manufacturing company, to enlarge its portfolio and strengthen its export capabilities to serve the automotive bearing market.
Some of the major players operating in the automotive bearing market are JTEKT Corporation, MINEBEA MITSUMI Inc., NSK Ltd., NTN Corporation, Schaeffler AG, The Timken Company, AB SKF, RBC Bearings Inc., NACHI-FUJIKOSHI CORP., C&U Group Ltd., and others.
*More Reports by P&S Intelligence*
*Automotive Window and Sealing Systems Market*
Urbanization, particularly in developing economies of the world, such as China and India, has been on the rise. There has been significant improvement in the lifestyle and living standard of people in these economies in the recent past, resulting in an increase in their purchasing power. This has allowed consumers in these countries to spend a significant share of their income on the purchase of vehicles for personal use, which, in turn, has positively affected the sales of automotive window and sealing systems.
*https://www.psmarketresearch.com/market-analysis/automotive-window-and-sealing-systems-market*
*Armored Vehicles Market*
Europe accounted for the largest region in the global armored vehicles market, where Germany contributed to the largest revenue. The U.S. was the major market for armored vehicles in North America, whereas Japan contributed to the largest revenue in Asia-Pacific region. Saudi Arabia generated the largest revenue for armored vehicles in the Middle East and Africa; whereas Brazil is expected to lead the global market for armored vehicles during the forecast period.
*https://www.psmarketresearch.com/market-analysis/armored-vehicles-market*
*About P&S Intelligence*
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
*Contact:*
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
*Connect with us: *LinkedIn* | *Twitter* | *Google +* | *Facebook Reported by GlobeNewswire 1 hour ago.
↧
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Results from this short clinical pharmacology trial inform and support further clinical development of ensifentrine as an add-on to dual and triple COPD therapyInvestment community conference call scheduled for 8 am EST on Monday, January 14, 2019
LONDON, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces top-line data from its three-day Phase 2 clinical pharmacology trial evaluating the effect of two different doses (1.5 mg and 6.0 mg; twice daily) of nebulized ensifentrine (RPL554) when used on top of an inhaled long-acting muscarinic antagonist/long-acting beta2 agonist (“LAMA/LABA”), tiotropium/olodaterol (Stiolto^® Respimat^®). LAMA/LABA therapies are commonly used in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). Patients already receiving inhaled corticosteroid (“ICS”) therapy were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use.
Ensifentrine is an investigational first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have bronchodilator and anti-inflammatory properties, which is currently in development for the maintenance treatment of COPD, cystic fibrosis and asthma.
*Highlights*
· Primary endpoint of peak forced expiratory volume in one second (“FEV[1]”) after morning dose on day 3 of treatment was not met with statistical significance, although the ensifentrine 1.5 mg morning dose improved peak FEV[1] by 46 mL, compared to placebo.
- Improvement in FEV[1], compared to placebo, with the 1.5 mg dose was maintained throughout the 24-hour period as measured on day 3.
· Importantly, peak FEV[1] after evening dose on day 3 showed statistically significant improvement, compared to placebo, with both doses, with ensifentrine 1.5 mg showing a 130 mL improvement (p · Ensifentrine at a 1.5 mg dose produced consistent improvements, compared to placebo, in average FEV[1] over 12 hours following the morning dose on days 1 to 3, with an improvement of approximately 50 mL on day 3. These improvements were not shown to be statistically significant when adjusted for multiple doses.
· Reductions in residual volume, compared to placebo, as measured by plethysmography were observed at all time points on day 3 with the 1.5 mg dose.
- Statistically significant reductions in mean residual volume were observed 15 minutes following the evening dose on day 3, with ensifentrine 1.5 mg showing a reduction of 259 mL (p · Ensifentrine 6.0 mg did not result in greater improvement in lung function as compared with the ensifentrine 1.5 mg dose.
· Ensifentrine was well tolerated at both doses with an adverse event profile consistent with that observed in prior studies.
“Achieving additional bronchodilator response of this magnitude in COPD patients that have previously been considered to be maximally bronchodilated on background dual or triple therapy in a short, three-day study is clinically meaningful and unprecedented,” commented Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, University of Manchester. “The statistically significant reduction observed in residual volume for the ensifentrine 1.5 mg dose at certain time points, which is closely related to dyspnea or breathlessness, highlights the potential for ensifentrine to provide symptomatic improvement for patients with this progressive and debilitating disease. I look forward to seeing data from longer-term studies evaluating the bronchodilator and anti-inflammatory activity of this unique mechanism of action."
“Having demonstrated in previous studies the potential of ensifentrine to deliver benefits to patients on no or single bronchodilator therapy, we believe that this short study continues to support our view that ensifentrine may also be of benefit to more severe COPD patients on dual and triple therapy, for whom there are few other treatment options,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “While we are disappointed that this exploratory Phase 2 study did not achieve statistical significance for its primary endpoint, these data give us clarity on the design, including dose and background therapy, for future long-term studies. We now have the opportunity to also include patients on dual and triple therapy, with the goal of further evaluating ensifentrine’s potential to produce sustained bronchodilation and anti-inflammatory effect in this large number of symptomatic COPD patients."
In Phase 2 clinical trials completed to date, ensifentrine has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators, and has also shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. Verona Pharma is currently conducting a Phase 2 trial to evaluate a dry powder inhaler formulation of ensifentrine for the maintenance treatment of COPD. The company also plans to evaluate ensifentrine in a metered-dose inhaler formulation as part of a comprehensive clinical program intended to fully demonstrate the clinical utility of ensifentrine in improving the standard of care for COPD.
*Study Design*
This study was a randomized, double-blind, three-way crossover trial (ClinicalTrials.gov Identifier: NCT0367367), conducted at sites in the U.S. and in the U.K., which enrolled 79 patients with COPD to investigate the efficacy and safety of nebulized ensifentrine (RPL554) on top of an inhaled LAMA/LABA, tiotropium/olodaterol (Stiolto^® Respimat^®), compared to placebo. Approximately 40% of patients were already receiving ICS anti-inflammatory therapy before the study and were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use. Following a 7- to 14-day washout period in advance of dosing and between study arms, patients received three days of treatment with each of two dose strengths (1.5 mg or 6.0 mg) of nebulized ensifentrine or placebo twice daily. The primary endpoint of this trial was improvement in lung function with ensifentrine (as an add-on to tiotropium/olodaterol), compared to placebo, as measured by FEV[1], a standard measure of exhaled breath volume to evaluate respiratory function, four hours post-dose after the morning dose on day three. Secondary endpoints included lung function as measured by FEV[1] over time, reductions in residual volume, and safety and tolerability.
*Conference Call*
Verona Pharma will host an investment community conference call today at 8:00 a.m. Eastern Standard Time (1:00 p.m. Greenwich Mean Time) on Monday, January 14, 2019 to discuss the top-line data from the study disclosed in this press release.
Analysts and investors may participate in the conference call by utilizing the conference ID: 13686524 and dialing the following numbers:
· 1-877-423-9813 or + 1-201-689-8573 for callers in the United States
· 0 800 756 3429 for callers in the United Kingdom
· 0 800 182 0040 for callers in Germany
Those interested in listening to the conference call live via the internet may do so by visiting the “Events and Presentations” page on the “Investors” section of Verona Pharma’s website at http://investors.veronapharma.com/events-and-presentations/events and clicking on the webcast link. Slides highlighting the top-line data will also be posted to the “Events and Presentations” page.
*THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.*
*About Chronic Obstructive Pulmonary Disease*
Chronic obstructive pulmonary disease (“COPD”) is a progressive and life-threatening respiratory disease for which there is no cure. Although COPD is thought to be underdiagnosed, globally, around 384 million people suffer from the disease. This number, according to the World Health Organization, is likely to increase in coming years, with estimates that COPD will become the third leading cause of death worldwide by 2030. The condition damages the airways and the lungs, leading to persistent symptoms of breathlessness, impacting a person’s daily life and their ability to perform simple activities such as walking a short flight of stairs or carrying a suitcase. Many experience acute periods of worsening symptoms called ‘exacerbations’, often leading to emergency department visits or hospital admissions and are also associated with high mortality. In the United States alone, the 2010 total annual medical costs related to COPD were estimated to be $32 billion and are projected to rise to $49 billion in 2020. About 30-40% of moderate to severe COPD patients on triple inhaled therapy (ICS/LAMA/LABA) remain uncontrolled and continue to experience airway obstruction (breathing difficulties), COPD symptoms and exacerbations. There is an urgent need for drugs with novel mechanisms of action that can be used by these patients in addition to current therapies.
*About Verona Pharma plc*
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine, is an investigational first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that is designed to act as both a bronchodilator and an anti-inflammatory agent in a single compound. In previous clinical trials, the nebulized formulation of ensifentrine has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva^®), compared with such bronchodilators administered as a single agent. Ensifentrine improved FEV[1] over four weeks in patients with moderate-to-severe COPD when compared to placebo and improved COPD symptoms and quality of life in a Phase 2b multicenter European study performed in 403 patients. In addition, ensifentrine has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. Ensifentrine has been well tolerated in these studies, having been administered to more than 800 subjects in 13 clinical trials. Verona Pharma is developing ensifentrine for the treatment of COPD, CF, and asthma.
*Forward-Looking Statements*
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements that there is an opportunity for additional bronchodilator and symptomatic improvement via the novel mechanism of action of ensifentrine and Verona Pharma’s plans to carry out further long-term clinical studies of ensifentrine as an add-on to both single and dual bronchodilator therapy and the expectation that even more profound anti-inflammatory effects, leading to improvements in lung function, as well as improvements in symptoms will result.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of RPL554, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of RPL554, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with RPL554, which could adversely affect our ability to develop or commercialize RPL554; potential delays in enrolling patients, which could adversely affect our research and development efforts; we may not be successful in developing RPL554 for multiple indications; our ability to obtain approval for and commercialize RPL554 in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize RPL554; and lawsuits related to patents covering RPL554 and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on February 27, 2018, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
*For further information, please contact:*
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker) Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
Darcie Robinson
Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
Reported by GlobeNewswire 1 hour ago.
LONDON, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces top-line data from its three-day Phase 2 clinical pharmacology trial evaluating the effect of two different doses (1.5 mg and 6.0 mg; twice daily) of nebulized ensifentrine (RPL554) when used on top of an inhaled long-acting muscarinic antagonist/long-acting beta2 agonist (“LAMA/LABA”), tiotropium/olodaterol (Stiolto^® Respimat^®). LAMA/LABA therapies are commonly used in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). Patients already receiving inhaled corticosteroid (“ICS”) therapy were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use.
Ensifentrine is an investigational first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have bronchodilator and anti-inflammatory properties, which is currently in development for the maintenance treatment of COPD, cystic fibrosis and asthma.
*Highlights*
· Primary endpoint of peak forced expiratory volume in one second (“FEV[1]”) after morning dose on day 3 of treatment was not met with statistical significance, although the ensifentrine 1.5 mg morning dose improved peak FEV[1] by 46 mL, compared to placebo.
- Improvement in FEV[1], compared to placebo, with the 1.5 mg dose was maintained throughout the 24-hour period as measured on day 3.
· Importantly, peak FEV[1] after evening dose on day 3 showed statistically significant improvement, compared to placebo, with both doses, with ensifentrine 1.5 mg showing a 130 mL improvement (p · Ensifentrine at a 1.5 mg dose produced consistent improvements, compared to placebo, in average FEV[1] over 12 hours following the morning dose on days 1 to 3, with an improvement of approximately 50 mL on day 3. These improvements were not shown to be statistically significant when adjusted for multiple doses.
· Reductions in residual volume, compared to placebo, as measured by plethysmography were observed at all time points on day 3 with the 1.5 mg dose.
- Statistically significant reductions in mean residual volume were observed 15 minutes following the evening dose on day 3, with ensifentrine 1.5 mg showing a reduction of 259 mL (p · Ensifentrine 6.0 mg did not result in greater improvement in lung function as compared with the ensifentrine 1.5 mg dose.
· Ensifentrine was well tolerated at both doses with an adverse event profile consistent with that observed in prior studies.
“Achieving additional bronchodilator response of this magnitude in COPD patients that have previously been considered to be maximally bronchodilated on background dual or triple therapy in a short, three-day study is clinically meaningful and unprecedented,” commented Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, University of Manchester. “The statistically significant reduction observed in residual volume for the ensifentrine 1.5 mg dose at certain time points, which is closely related to dyspnea or breathlessness, highlights the potential for ensifentrine to provide symptomatic improvement for patients with this progressive and debilitating disease. I look forward to seeing data from longer-term studies evaluating the bronchodilator and anti-inflammatory activity of this unique mechanism of action."
“Having demonstrated in previous studies the potential of ensifentrine to deliver benefits to patients on no or single bronchodilator therapy, we believe that this short study continues to support our view that ensifentrine may also be of benefit to more severe COPD patients on dual and triple therapy, for whom there are few other treatment options,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “While we are disappointed that this exploratory Phase 2 study did not achieve statistical significance for its primary endpoint, these data give us clarity on the design, including dose and background therapy, for future long-term studies. We now have the opportunity to also include patients on dual and triple therapy, with the goal of further evaluating ensifentrine’s potential to produce sustained bronchodilation and anti-inflammatory effect in this large number of symptomatic COPD patients."
In Phase 2 clinical trials completed to date, ensifentrine has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators, and has also shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. Verona Pharma is currently conducting a Phase 2 trial to evaluate a dry powder inhaler formulation of ensifentrine for the maintenance treatment of COPD. The company also plans to evaluate ensifentrine in a metered-dose inhaler formulation as part of a comprehensive clinical program intended to fully demonstrate the clinical utility of ensifentrine in improving the standard of care for COPD.
*Study Design*
This study was a randomized, double-blind, three-way crossover trial (ClinicalTrials.gov Identifier: NCT0367367), conducted at sites in the U.S. and in the U.K., which enrolled 79 patients with COPD to investigate the efficacy and safety of nebulized ensifentrine (RPL554) on top of an inhaled LAMA/LABA, tiotropium/olodaterol (Stiolto^® Respimat^®), compared to placebo. Approximately 40% of patients were already receiving ICS anti-inflammatory therapy before the study and were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use. Following a 7- to 14-day washout period in advance of dosing and between study arms, patients received three days of treatment with each of two dose strengths (1.5 mg or 6.0 mg) of nebulized ensifentrine or placebo twice daily. The primary endpoint of this trial was improvement in lung function with ensifentrine (as an add-on to tiotropium/olodaterol), compared to placebo, as measured by FEV[1], a standard measure of exhaled breath volume to evaluate respiratory function, four hours post-dose after the morning dose on day three. Secondary endpoints included lung function as measured by FEV[1] over time, reductions in residual volume, and safety and tolerability.
*Conference Call*
Verona Pharma will host an investment community conference call today at 8:00 a.m. Eastern Standard Time (1:00 p.m. Greenwich Mean Time) on Monday, January 14, 2019 to discuss the top-line data from the study disclosed in this press release.
Analysts and investors may participate in the conference call by utilizing the conference ID: 13686524 and dialing the following numbers:
· 1-877-423-9813 or + 1-201-689-8573 for callers in the United States
· 0 800 756 3429 for callers in the United Kingdom
· 0 800 182 0040 for callers in Germany
Those interested in listening to the conference call live via the internet may do so by visiting the “Events and Presentations” page on the “Investors” section of Verona Pharma’s website at http://investors.veronapharma.com/events-and-presentations/events and clicking on the webcast link. Slides highlighting the top-line data will also be posted to the “Events and Presentations” page.
*THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.*
*About Chronic Obstructive Pulmonary Disease*
Chronic obstructive pulmonary disease (“COPD”) is a progressive and life-threatening respiratory disease for which there is no cure. Although COPD is thought to be underdiagnosed, globally, around 384 million people suffer from the disease. This number, according to the World Health Organization, is likely to increase in coming years, with estimates that COPD will become the third leading cause of death worldwide by 2030. The condition damages the airways and the lungs, leading to persistent symptoms of breathlessness, impacting a person’s daily life and their ability to perform simple activities such as walking a short flight of stairs or carrying a suitcase. Many experience acute periods of worsening symptoms called ‘exacerbations’, often leading to emergency department visits or hospital admissions and are also associated with high mortality. In the United States alone, the 2010 total annual medical costs related to COPD were estimated to be $32 billion and are projected to rise to $49 billion in 2020. About 30-40% of moderate to severe COPD patients on triple inhaled therapy (ICS/LAMA/LABA) remain uncontrolled and continue to experience airway obstruction (breathing difficulties), COPD symptoms and exacerbations. There is an urgent need for drugs with novel mechanisms of action that can be used by these patients in addition to current therapies.
*About Verona Pharma plc*
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine, is an investigational first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that is designed to act as both a bronchodilator and an anti-inflammatory agent in a single compound. In previous clinical trials, the nebulized formulation of ensifentrine has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva^®), compared with such bronchodilators administered as a single agent. Ensifentrine improved FEV[1] over four weeks in patients with moderate-to-severe COPD when compared to placebo and improved COPD symptoms and quality of life in a Phase 2b multicenter European study performed in 403 patients. In addition, ensifentrine has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. Ensifentrine has been well tolerated in these studies, having been administered to more than 800 subjects in 13 clinical trials. Verona Pharma is developing ensifentrine for the treatment of COPD, CF, and asthma.
*Forward-Looking Statements*
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements that there is an opportunity for additional bronchodilator and symptomatic improvement via the novel mechanism of action of ensifentrine and Verona Pharma’s plans to carry out further long-term clinical studies of ensifentrine as an add-on to both single and dual bronchodilator therapy and the expectation that even more profound anti-inflammatory effects, leading to improvements in lung function, as well as improvements in symptoms will result.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of RPL554, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of RPL554, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with RPL554, which could adversely affect our ability to develop or commercialize RPL554; potential delays in enrolling patients, which could adversely affect our research and development efforts; we may not be successful in developing RPL554 for multiple indications; our ability to obtain approval for and commercialize RPL554 in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize RPL554; and lawsuits related to patents covering RPL554 and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on February 27, 2018, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
*For further information, please contact:*
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker) Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
Darcie Robinson
Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
Reported by GlobeNewswire 1 hour ago.
↧
↧
Lithium Werks appoints T. Joseph Fisher III as chairman
HENGELO, Netherlands, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Dutch energy storage and battery company Lithium Werks B.V. (www.lithiumwerks.com) has appointed T. Joseph (Joe) Fisher III as chairman of the board.Fisher, who has been the company’s chief executive since he co-founded the company in 2017, is a 30-year veteran in the battery industry.
He will now also step into the role as chairman of Lithium Werks, while Kees Koolen will focus on the development of a separate battery company. Koolen remains a shareholder and supporter of Lithium Werks, and the two companies will continue to cooperate closely going forward.
“We are committed to playing a leading role in society’s energy transition to renewables such as solar and wind and our strategy remains unchanged,” Fisher said.
“We anticipate particularly strong growth in Europe, where battery demand appears to be insatiable. There is growing awareness amongst policymakers, companies and civilians that we will need batteries to ensure the lights don’t go out when there is no wind and the sun isn’t shining. As a European battery company, we are competitively positioned to deliver what our fast-growing customer base requires."
“As energy storage is an essential part of the energy transition, in Europe and across the world, we expect demand for lithium-ion batteries to grow tenfold over the next decade alone. Our industry must step up to the challenge and construct enough factories to deliver capacity in thousands of GWh over the next three decades.” said Fisher.
“Our expertise in safe, reliable, clean and sustainable energy storage solutions engendered dramatic growth in 2018. As we enter 2019, we expect to expand further in response to soaring demand through both organic growth and further acquisitions, including our future factory plans in China with our local partners.”
Lithium Werks, which already has three smaller battery facilities in China and has operations across three continents, plans to build multiple giga factories. The factories and related facilities will produce battery cells and systems for lithium-ion batteries to be used for energy storage and smart grids, as well as for large transportation equipment and industrial applications.
*About Lithium Werks*
Lithium Werks is a fast-growing global lithium-ion battery company, headquartered in Hengelo, the Netherlands, with production facilities in China and offices and warehousing facilities in the Netherlands, the US, the UK and Norway. Lithium Werks provides cells, modules and energy management systems to industrial, transportation, marine and clean energy storage markets.
CONTACT: Media Relations
LWmarketing@lithiumwerks.com
+44 (0)28 9084 5411
Investor Relations
Investor.Relations@lithiumwerks.com Reported by GlobeNewswire 1 hour ago.
He will now also step into the role as chairman of Lithium Werks, while Kees Koolen will focus on the development of a separate battery company. Koolen remains a shareholder and supporter of Lithium Werks, and the two companies will continue to cooperate closely going forward.
“We are committed to playing a leading role in society’s energy transition to renewables such as solar and wind and our strategy remains unchanged,” Fisher said.
“We anticipate particularly strong growth in Europe, where battery demand appears to be insatiable. There is growing awareness amongst policymakers, companies and civilians that we will need batteries to ensure the lights don’t go out when there is no wind and the sun isn’t shining. As a European battery company, we are competitively positioned to deliver what our fast-growing customer base requires."
“As energy storage is an essential part of the energy transition, in Europe and across the world, we expect demand for lithium-ion batteries to grow tenfold over the next decade alone. Our industry must step up to the challenge and construct enough factories to deliver capacity in thousands of GWh over the next three decades.” said Fisher.
“Our expertise in safe, reliable, clean and sustainable energy storage solutions engendered dramatic growth in 2018. As we enter 2019, we expect to expand further in response to soaring demand through both organic growth and further acquisitions, including our future factory plans in China with our local partners.”
Lithium Werks, which already has three smaller battery facilities in China and has operations across three continents, plans to build multiple giga factories. The factories and related facilities will produce battery cells and systems for lithium-ion batteries to be used for energy storage and smart grids, as well as for large transportation equipment and industrial applications.
*About Lithium Werks*
Lithium Werks is a fast-growing global lithium-ion battery company, headquartered in Hengelo, the Netherlands, with production facilities in China and offices and warehousing facilities in the Netherlands, the US, the UK and Norway. Lithium Werks provides cells, modules and energy management systems to industrial, transportation, marine and clean energy storage markets.
CONTACT: Media Relations
LWmarketing@lithiumwerks.com
+44 (0)28 9084 5411
Investor Relations
Investor.Relations@lithiumwerks.com Reported by GlobeNewswire 1 hour ago.
↧
Lundin Petroleum announces increased reserves and contingent resources
*Lundin Petroleum AB (Lundin Petroleum) is pleased to announce that as at 31 December 2018, its proved plus probable net reserves (2P reserves) are 745 million barrels of oil equivalent (MMboe), its proved plus probable plus possible net reserves (3P reserves) are 901 MMboe and its best estimate net contingent resources (contingent resources) are 225 MMboe. The 2P reserves replacement ratio is 163 percent for 2018 and this is the fifth consecutive year that Lundin Petroleum has more than replaced production.^1*
Lundin Petroleum’s 2P reserves as at 31 December 2018 are 745.4 MMboe and reflect a positive revision of 49.2 MMboe, excluding sales. The 3P reserves as at 31 December 2018 are 900.9 MMboe and reflect a positive revision of 35.4 MMboe, excluding sales.^ 2,3
* * *2P
Reserves* *3P *
*Reserves*
*End 2017* *726.3* *895.5*
- Produced^4 -30.1 -30.1
+ Revisions + 49.2 + 35.4
*End 2018* *745.4* *900.9*
*Reserves replacement ratio*^5 *163%* *118%*The increase in reserves relates mainly to Lundin Petroleum’s largest asset, the Johan Sverdrup field, with minor reserves additions on Edvard Grieg and the Alvheim area also contributing to the result. Oil accounts for 94 percent of Lundin Petroleum’s 2P reserves and when the Johan Sverdrup field commences production, with expected start-up in November 2019, the majority of Lundin Petroleum’s 2P reserves will be in production.
The reserves upgrade on Johan Sverdrup is driven by positive drilling results and promotion of the water alternate gas (WAG) injection project from contingent resources to reserves, which was sanctioned by the partnership during 2018. The upgrade of reserves in the Johan Sverdrup field are consistent with the upgrades announced by the operator Equinor during 2018.
Edvard Grieg production performance continues to exceed expectations with significantly slower build-up of water production than anticipated, leading to around a six months extension of plateau production to mid-2020. As part of the reservoir monitoring programme, a 4D seismic survey over the Edvard Grieg field was acquired during 2018 which confirms that the water injection flood front is further away from the main production wells than predicted by the current reservoir models. This information is still under review and has not been incorporated into the reservoir models used to support the year end 2018 reserves estimate. An infill drilling programme is planned at Edvard Grieg commencing in 2020, and the sanction of this project, which is anticipated during 2019, will allow for the promotion of the associated 10 MMboe net contingent resources to 2P reserves, based on a three well programme.
Lundin Petroleum’s contingent resources as at 31 December 2018 are 225 MMboe, which represents an increase of 40 MMboe from year end 2017, before projects matured to reserves. New discoveries on Frosk in the Alvheim area and Lille Prinsen in the Utsira High area and positive results from the appraisal wells on Luno II, Rolvsnes and Gekko, together with the acquisition of an additional 15 percent interest in Luno II are the main drivers for the increase. The large amount of new information from the positive results from the Alta extended well test (EWT) and latest generation 3D seismic survey (TopSeis) over the entire Alta and Gohta area is still being evaluated. Consequently, contingent resources for the Alta and Gohta discoveries are unchanged from year end 2017 and will be updated during 2019 when the future appraisal plan for the area is defined and all the additional data has been processed.
Phase 1 of the Luno II development project is expected to be sanctioned in the first quarter of 2019, which will allow for 37 MMboe of net contingent resources to be promoted to 2P reserves. Additionally, the Rolvsnes EWT is expected to be sanctioned during the first quarter of 2019 and will be developed in parallel with the Luno II project.
The reserves estimates have been audited by ERCE, a third party independent reserves auditor, and have been calculated using 2007 Petroleum Resource Management System (SPE PRMS), Guidelines of the Society of Petroleum Engineers (SPE), World Petroleum Congress (WPC), American Association of Petroleum Geologists (AAPG) and Society of Petroleum Evaluation Engineers (SPEE). The contingent resource estimates associated to the Edvard Grieg, Alvheim area, Johan Sverdrup and Luno II assets have been audited by ERCE. For the other assets, the contingent resource volumes are based on management estimates.
*Nick Walker, COO of Lundin Petroleum commented:*
“In 2018, we increased both reserves and contingent resources, once again highlighting the impact our organic growth strategy has in continuing to deliver the E&P cycle of adding contingent resources and converting it into reserves and then production. This is the fifth consecutive year in which our reserve additions have more than replaced production, whilst in the same period production has significantly increased and as we continue to invest in the portfolio during 2019, I am confident in our ability to continue to grow organically.”
^1 Relates to Lundin Petroleum’s portfolio in Norway.
^2 BOE’s may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 Mcf : 1 Bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent the value equivalency at the wellhead.
^3 The reserves were calculated using a nominal Brent oil price of USD 66 per barrel in 2019, 70 in 2020, 71 in 2021, 74 in 2022, 75 in 2023, 78 in 2024, 80 in 2025, 81 in 2026, 83 in 2027, 84 in 2028 and increasing by 2 percent per year thereafter.
^4 Reserves are measured in salable quantities (saleable oil, natural gas liquids and dry gas converted to oil equivalents), which may differ from production volumes provided in corporate reports which are given in wellhead production quantities (oil and rich gas converted to oil equivalents).
^5 As per industry standards the reserves replacement ratio is defined as the ratio of reserves additions to production during the year, excluding sales and acquisitions.
Lundin Petroleum is one of Europe’s leading independent oil and gas exploration and production companies with operations focused on Norway and listed on Nasdaq Stockholm (ticker "LUPE"). Read more about Lundin Petroleum’s business and operations at www.lundin-petroleum.comFor further information, please contact:
Edward Westropp
VP Investor Relations
Tel: +41 22 595 10 14
edward.westropp@lundin.ch
Sofia Antunes
Investor Relations Officer
Tel: +41 795 23 60 75
sofia.antunes@lundin.ch Robert Eriksson
Manager, Media Communications
Tel: +46 701 11 26 15
robert.eriksson@lundin-petroleum.seThis is information that Lundin Petroleum AB is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact persons set out above, at 0800 CET on 14 January 2019.
*Forward-Looking Statements *
Certain statements made and information contained herein constitute "forward-looking information" (within the meaning of applicable securities legislation). Such statements and information (together, "forward-looking statements") relate to future events, including the Company's future performance, business prospects or opportunities. Forward-looking statements include, but are not limited to, statements with respect to estimates of reserves and/or resources, future production levels, future capital expenditures and their allocation to exploration and development activities, future drilling and other exploration and development activities. Ultimate recovery of reserves or resources are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.
All statements other than statements of historical fact may be forward-looking statements. Statements concerning proven and probable reserves and resource estimates may also be deemed to constitute forward-looking statements and reflect conclusions that are based on certain assumptions that the reserves and resources can be economically exploited. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar expressions) are not statements of historical fact and may be "forward-looking statements". Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. No assurance can be given that these expectations and assumptions will prove to be correct and such forward-looking statements should not be relied upon. These statements speak only as on the date of the information and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws. These forward-looking statements involve risks and uncertainties relating to, among other things, operational risks (including exploration and development risks), productions costs, availability of drilling equipment, reliance on key personnel, reserve estimates, health, safety and environmental issues, legal risks and regulatory changes, competition, geopolitical risk, and financial risks. These risks and uncertainties are described in more detail under the heading “Risks and Risk Management” and elsewhere in the Company’s annual report. Readers are cautioned that the foregoing list of risk factors should not be construed as exhaustive. Actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are expressly qualified by this cautionary statement.
--------------------*Attachment*
· Lundin Petroleum - Reserves and Resources Audit - V1- 20190114en Reported by GlobeNewswire 1 hour ago.
Lundin Petroleum’s 2P reserves as at 31 December 2018 are 745.4 MMboe and reflect a positive revision of 49.2 MMboe, excluding sales. The 3P reserves as at 31 December 2018 are 900.9 MMboe and reflect a positive revision of 35.4 MMboe, excluding sales.^ 2,3
* * *2P
Reserves* *3P *
*Reserves*
*End 2017* *726.3* *895.5*
- Produced^4 -30.1 -30.1
+ Revisions + 49.2 + 35.4
*End 2018* *745.4* *900.9*
*Reserves replacement ratio*^5 *163%* *118%*The increase in reserves relates mainly to Lundin Petroleum’s largest asset, the Johan Sverdrup field, with minor reserves additions on Edvard Grieg and the Alvheim area also contributing to the result. Oil accounts for 94 percent of Lundin Petroleum’s 2P reserves and when the Johan Sverdrup field commences production, with expected start-up in November 2019, the majority of Lundin Petroleum’s 2P reserves will be in production.
The reserves upgrade on Johan Sverdrup is driven by positive drilling results and promotion of the water alternate gas (WAG) injection project from contingent resources to reserves, which was sanctioned by the partnership during 2018. The upgrade of reserves in the Johan Sverdrup field are consistent with the upgrades announced by the operator Equinor during 2018.
Edvard Grieg production performance continues to exceed expectations with significantly slower build-up of water production than anticipated, leading to around a six months extension of plateau production to mid-2020. As part of the reservoir monitoring programme, a 4D seismic survey over the Edvard Grieg field was acquired during 2018 which confirms that the water injection flood front is further away from the main production wells than predicted by the current reservoir models. This information is still under review and has not been incorporated into the reservoir models used to support the year end 2018 reserves estimate. An infill drilling programme is planned at Edvard Grieg commencing in 2020, and the sanction of this project, which is anticipated during 2019, will allow for the promotion of the associated 10 MMboe net contingent resources to 2P reserves, based on a three well programme.
Lundin Petroleum’s contingent resources as at 31 December 2018 are 225 MMboe, which represents an increase of 40 MMboe from year end 2017, before projects matured to reserves. New discoveries on Frosk in the Alvheim area and Lille Prinsen in the Utsira High area and positive results from the appraisal wells on Luno II, Rolvsnes and Gekko, together with the acquisition of an additional 15 percent interest in Luno II are the main drivers for the increase. The large amount of new information from the positive results from the Alta extended well test (EWT) and latest generation 3D seismic survey (TopSeis) over the entire Alta and Gohta area is still being evaluated. Consequently, contingent resources for the Alta and Gohta discoveries are unchanged from year end 2017 and will be updated during 2019 when the future appraisal plan for the area is defined and all the additional data has been processed.
Phase 1 of the Luno II development project is expected to be sanctioned in the first quarter of 2019, which will allow for 37 MMboe of net contingent resources to be promoted to 2P reserves. Additionally, the Rolvsnes EWT is expected to be sanctioned during the first quarter of 2019 and will be developed in parallel with the Luno II project.
The reserves estimates have been audited by ERCE, a third party independent reserves auditor, and have been calculated using 2007 Petroleum Resource Management System (SPE PRMS), Guidelines of the Society of Petroleum Engineers (SPE), World Petroleum Congress (WPC), American Association of Petroleum Geologists (AAPG) and Society of Petroleum Evaluation Engineers (SPEE). The contingent resource estimates associated to the Edvard Grieg, Alvheim area, Johan Sverdrup and Luno II assets have been audited by ERCE. For the other assets, the contingent resource volumes are based on management estimates.
*Nick Walker, COO of Lundin Petroleum commented:*
“In 2018, we increased both reserves and contingent resources, once again highlighting the impact our organic growth strategy has in continuing to deliver the E&P cycle of adding contingent resources and converting it into reserves and then production. This is the fifth consecutive year in which our reserve additions have more than replaced production, whilst in the same period production has significantly increased and as we continue to invest in the portfolio during 2019, I am confident in our ability to continue to grow organically.”
^1 Relates to Lundin Petroleum’s portfolio in Norway.
^2 BOE’s may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 Mcf : 1 Bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent the value equivalency at the wellhead.
^3 The reserves were calculated using a nominal Brent oil price of USD 66 per barrel in 2019, 70 in 2020, 71 in 2021, 74 in 2022, 75 in 2023, 78 in 2024, 80 in 2025, 81 in 2026, 83 in 2027, 84 in 2028 and increasing by 2 percent per year thereafter.
^4 Reserves are measured in salable quantities (saleable oil, natural gas liquids and dry gas converted to oil equivalents), which may differ from production volumes provided in corporate reports which are given in wellhead production quantities (oil and rich gas converted to oil equivalents).
^5 As per industry standards the reserves replacement ratio is defined as the ratio of reserves additions to production during the year, excluding sales and acquisitions.
Lundin Petroleum is one of Europe’s leading independent oil and gas exploration and production companies with operations focused on Norway and listed on Nasdaq Stockholm (ticker "LUPE"). Read more about Lundin Petroleum’s business and operations at www.lundin-petroleum.comFor further information, please contact:
Edward Westropp
VP Investor Relations
Tel: +41 22 595 10 14
edward.westropp@lundin.ch
Sofia Antunes
Investor Relations Officer
Tel: +41 795 23 60 75
sofia.antunes@lundin.ch Robert Eriksson
Manager, Media Communications
Tel: +46 701 11 26 15
robert.eriksson@lundin-petroleum.seThis is information that Lundin Petroleum AB is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact persons set out above, at 0800 CET on 14 January 2019.
*Forward-Looking Statements *
Certain statements made and information contained herein constitute "forward-looking information" (within the meaning of applicable securities legislation). Such statements and information (together, "forward-looking statements") relate to future events, including the Company's future performance, business prospects or opportunities. Forward-looking statements include, but are not limited to, statements with respect to estimates of reserves and/or resources, future production levels, future capital expenditures and their allocation to exploration and development activities, future drilling and other exploration and development activities. Ultimate recovery of reserves or resources are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.
All statements other than statements of historical fact may be forward-looking statements. Statements concerning proven and probable reserves and resource estimates may also be deemed to constitute forward-looking statements and reflect conclusions that are based on certain assumptions that the reserves and resources can be economically exploited. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar expressions) are not statements of historical fact and may be "forward-looking statements". Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. No assurance can be given that these expectations and assumptions will prove to be correct and such forward-looking statements should not be relied upon. These statements speak only as on the date of the information and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws. These forward-looking statements involve risks and uncertainties relating to, among other things, operational risks (including exploration and development risks), productions costs, availability of drilling equipment, reliance on key personnel, reserve estimates, health, safety and environmental issues, legal risks and regulatory changes, competition, geopolitical risk, and financial risks. These risks and uncertainties are described in more detail under the heading “Risks and Risk Management” and elsewhere in the Company’s annual report. Readers are cautioned that the foregoing list of risk factors should not be construed as exhaustive. Actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are expressly qualified by this cautionary statement.
--------------------*Attachment*
· Lundin Petroleum - Reserves and Resources Audit - V1- 20190114en Reported by GlobeNewswire 1 hour ago.
↧
Nexstim Plc Depression Therapy Business Update
Company announcement, Helsinki, 14 January 2019 at 09.00
*Nexstim Plc Depression Therapy Business Update*
Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), has shifted its resources and focus during year 2018 to generating Navigated Brain Therapy (NBT®) system sales for the treatment of MDD. This strategy has delivered good results with the company installing five NBT® depression therapy systems in the US since the launch of the depression indication in May of 2018. In Europe and rest of the world there are now a total of five NBT® systems installed for the treatment of depression.
All of the current NBT® systems in the US have been installed on a pay-per-use leasing model meaning that the majority of the NBT® therapy revenue from these systems will be recognized as net sales during year 2019. In the US, Nexstim is targeting an annual revenue level of about USD 100 thousand per installed NBT® system. The European TMS markets are more varied and less developed than the US. As a result, Nexstim has adopted different targeted revenue models, which take into account the mix of private and public payors in each of the countries it operates.
*Martin Jamieson, Chairman and CEO, Nexstim Plc commented:*" Nexstim's strategy of building shareholder value by capitalising on the significant potential of our SmartFocus^TM TMS for the treatment of MDD is making good progress. Our unique technology promises improved outcomes for patients with depression at a time when neuro-stimulation is rapidly gaining traction as a mainstream treatment modality. The unique navigational capability of our NBT® system, personalised to each patient for targeted stimulation of the relevant brain area, clearly differentiates it from other TMS devices currently on the market for MDD. We are looking at raising further funds to invest in our US commercial organisation to ensure that we can maximise the potential of our unique system in the very large US and growing MDD market. We would also like to invest more resources in driving our NBT system sales in Europe, where it is approved for a range of significant indications including MDD."
In order to fund the further commercialisation of Nexstim's therapy business the Company is currently evaluating a potential funding round that could be concluded during Q1 or early Q2 2019.
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
*Further information is available on the website www.nexstim.com or by contacting:*
Nexstim
Martin Jamieson, Chairman and CEO
+44 771 516 3942
martin.jamieson@nexstim.com
Sisu Partners Oy (Certified Adviser)
Jussi Majamaa
+ 358 40 842 4479
jussi.majamaa@sisupartners.com
Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
david.dible@citigatedewerogerson.com
*About Nexstim Plc*
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim's NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.
For more information please visit www.nexstim.com.
*Attachment*
· Nexstim Plc Depression Therapy Business Update.pdf Reported by GlobeNewswire 1 hour ago.
*Nexstim Plc Depression Therapy Business Update*
Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), has shifted its resources and focus during year 2018 to generating Navigated Brain Therapy (NBT®) system sales for the treatment of MDD. This strategy has delivered good results with the company installing five NBT® depression therapy systems in the US since the launch of the depression indication in May of 2018. In Europe and rest of the world there are now a total of five NBT® systems installed for the treatment of depression.
All of the current NBT® systems in the US have been installed on a pay-per-use leasing model meaning that the majority of the NBT® therapy revenue from these systems will be recognized as net sales during year 2019. In the US, Nexstim is targeting an annual revenue level of about USD 100 thousand per installed NBT® system. The European TMS markets are more varied and less developed than the US. As a result, Nexstim has adopted different targeted revenue models, which take into account the mix of private and public payors in each of the countries it operates.
*Martin Jamieson, Chairman and CEO, Nexstim Plc commented:*" Nexstim's strategy of building shareholder value by capitalising on the significant potential of our SmartFocus^TM TMS for the treatment of MDD is making good progress. Our unique technology promises improved outcomes for patients with depression at a time when neuro-stimulation is rapidly gaining traction as a mainstream treatment modality. The unique navigational capability of our NBT® system, personalised to each patient for targeted stimulation of the relevant brain area, clearly differentiates it from other TMS devices currently on the market for MDD. We are looking at raising further funds to invest in our US commercial organisation to ensure that we can maximise the potential of our unique system in the very large US and growing MDD market. We would also like to invest more resources in driving our NBT system sales in Europe, where it is approved for a range of significant indications including MDD."
In order to fund the further commercialisation of Nexstim's therapy business the Company is currently evaluating a potential funding round that could be concluded during Q1 or early Q2 2019.
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
*Further information is available on the website www.nexstim.com or by contacting:*
Nexstim
Martin Jamieson, Chairman and CEO
+44 771 516 3942
martin.jamieson@nexstim.com
Sisu Partners Oy (Certified Adviser)
Jussi Majamaa
+ 358 40 842 4479
jussi.majamaa@sisupartners.com
Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
david.dible@citigatedewerogerson.com
*About Nexstim Plc*
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim's NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.
For more information please visit www.nexstim.com.
*Attachment*
· Nexstim Plc Depression Therapy Business Update.pdf Reported by GlobeNewswire 1 hour ago.
↧
JCDecaux: Clarification from JCDecaux about the Sydney advertising street furniture city tender
*Clarification from JCDecaux about the Sydney advertising street furniture **city tender*
*Paris, January 14^th, 2019 *- JCDecaux S.A. (Euronext Paris: DEC), the number one outdoor advertising company worldwide, took notice of the press article posted on the Australian Financial Review website on January 10^th, 2019 - and relayed by some financial analyst's notes - reporting that "JCDecaux is believed to be the front runner to lock down the City of Sydney contract (.).".
JCDecaux is surprised by this information and other related information which is inaccurate since JCDecaux has made the decision not to submit any bid proposal under the current tender terms.
*Key Figures for JCDecaux*
· 2017 revenue: €3,493m*, H1 2018 revenue: €1,643m
· JCDecaux is listed on the Eurolist of Euronext Paris and is part of the Euronext 100 and Euronext Family Business indexes
· JCDecaux is part of the FTSE4Good index
· N°1 worldwide in street furniture (543,050 advertising panels)
· N°1 worldwide in transport advertising with more than 215 airports and 250 contracts in metros, buses, trains and tramways (356,320 advertising panels)
· N°1 in Europe for billboards (141,630 advertising panels)
· N°1 in outdoor advertising in Europe (672,220 advertising panels)
· N°1 in outdoor advertising in Asia-Pacific (216,290 advertising panels)
· N°1 in outdoor advertising in Latin America (77,190 advertising panels)
· N°1 in outdoor advertising in Africa (26,770 advertising panels)
· N°1 in outdoor advertising in the Middle-East (18,650 advertising panels)
· Leader in self-service bike rental scheme: pioneer in eco-friendly mobility
· 1,074,113 advertising panels in more than 80 countries
· Present in 4,033 cities with more than 10,000 inhabitants
· 13,040 employees
* Restated from the retrospective application of IFRS 15, applicable from January 1^st, 2018
*Communications Department**:* Agathe Albertini
+33 (0) 1 30 79 34 99 - agathe.albertini@jcdecaux.com
*Investor Relations**:* Arnaud Courtial
+33 (0) 1 30 79 79 93 - arnaud.courtial@jcdecaux.com
*Attachment*
· 14-01-2019 # APN - AO Sydney_UK.pdf Reported by GlobeNewswire 1 hour ago.
*Paris, January 14^th, 2019 *- JCDecaux S.A. (Euronext Paris: DEC), the number one outdoor advertising company worldwide, took notice of the press article posted on the Australian Financial Review website on January 10^th, 2019 - and relayed by some financial analyst's notes - reporting that "JCDecaux is believed to be the front runner to lock down the City of Sydney contract (.).".
JCDecaux is surprised by this information and other related information which is inaccurate since JCDecaux has made the decision not to submit any bid proposal under the current tender terms.
*Key Figures for JCDecaux*
· 2017 revenue: €3,493m*, H1 2018 revenue: €1,643m
· JCDecaux is listed on the Eurolist of Euronext Paris and is part of the Euronext 100 and Euronext Family Business indexes
· JCDecaux is part of the FTSE4Good index
· N°1 worldwide in street furniture (543,050 advertising panels)
· N°1 worldwide in transport advertising with more than 215 airports and 250 contracts in metros, buses, trains and tramways (356,320 advertising panels)
· N°1 in Europe for billboards (141,630 advertising panels)
· N°1 in outdoor advertising in Europe (672,220 advertising panels)
· N°1 in outdoor advertising in Asia-Pacific (216,290 advertising panels)
· N°1 in outdoor advertising in Latin America (77,190 advertising panels)
· N°1 in outdoor advertising in Africa (26,770 advertising panels)
· N°1 in outdoor advertising in the Middle-East (18,650 advertising panels)
· Leader in self-service bike rental scheme: pioneer in eco-friendly mobility
· 1,074,113 advertising panels in more than 80 countries
· Present in 4,033 cities with more than 10,000 inhabitants
· 13,040 employees
* Restated from the retrospective application of IFRS 15, applicable from January 1^st, 2018
*Communications Department**:* Agathe Albertini
+33 (0) 1 30 79 34 99 - agathe.albertini@jcdecaux.com
*Investor Relations**:* Arnaud Courtial
+33 (0) 1 30 79 79 93 - arnaud.courtial@jcdecaux.com
*Attachment*
· 14-01-2019 # APN - AO Sydney_UK.pdf Reported by GlobeNewswire 1 hour ago.
↧
↧
Opinion: Spurs have to ditch Trippier for one of Europe's best after Man United disaster-class
Tottenham must make Crystal Palace prodigy Aaron Wan-Bissaka their top transfer target after Kieran Trippier cost them dearly against Manchester United.
Reported by Football FanCast 34 minutes ago.
↧
US threatens EU companies with sanctions over Nord Steam 2, Turkish Stream
A transatlantic tiff over Europe’s natural gas supply came to the boil Sunday (13 January), as Donald Trump’s ambassador to Germany threatened firms involved in a pipeline from Russia with sanctions. At stake is a mixture of economic and security interests for...
Reported by EurActiv 27 minutes ago.
↧
EUR/USD clinches to gains near 1.1470
· *The pair alternates gains with losses early on Monday.*
· *The greenback appears sidelined around 95.60 so far.*
· *Disappointing Chinese trade data sparked risk-off sentiment.*
After moving to daily highs near 1.1480 during overnight trade, *EUR/USD* has come under some selling pressure and tested the mid-1.1400s, or session lows, just to rebound afterwards.
*EUR/USD struggles for direction below 1.1500*
The pair has started the week near the 100-day SMA around 1.1480, although disappointing trade figures in China during the last month of 2018 have prompted sellers to return to the markets.
In fact, Chinese exports and imports unexpectedly contracted at an annualized 4.4% and 7.6%, respectively, spooking investors and adding to the increasing view that a slowdown in the Asian economy could be in the offing.
Data wise in Euroland, November’s Industrial Production figures in the bloc will be the only release of note today.
*What to look for around EUR/USD*
In the very near term, the pair would look to the performance of the greenback and the broader risk-appetite trends for direction along with developments from the US-China trade negotiations. In the longer run, the ECB ‘data-dependency’ should grow in significance in light of the apparent slowdown in the region’s fundamentals. This, along with the omnipresent effervescence in the Italian political scenario, the upcoming discussions in the French budget and a potential technical recession in Germany in H2 2018 could somewhat limit the scope for gains in EUR. In addition, the EU Parliamentary elections in May could be a gauge of the current situation around the populism in Europe.
*EUR/USD levels to watch*
At the moment, the pair is up 0.03% at 1.1471 facing the next hurdle at 1.1569 (2019 high Jan.10) seconded by 1.1585 (61.8% Fibo of the September-November drop) and finally 1.1621 (high Oct.16 2018). On the flip side, a breakdown of 1.1447 (10-day SMA) would target 1.1411 (21-day SMA) en route to 1.1306 (2019 low Jan.3). Reported by FXstreet.com 9 minutes ago.
· *The greenback appears sidelined around 95.60 so far.*
· *Disappointing Chinese trade data sparked risk-off sentiment.*
After moving to daily highs near 1.1480 during overnight trade, *EUR/USD* has come under some selling pressure and tested the mid-1.1400s, or session lows, just to rebound afterwards.
*EUR/USD struggles for direction below 1.1500*
The pair has started the week near the 100-day SMA around 1.1480, although disappointing trade figures in China during the last month of 2018 have prompted sellers to return to the markets.
In fact, Chinese exports and imports unexpectedly contracted at an annualized 4.4% and 7.6%, respectively, spooking investors and adding to the increasing view that a slowdown in the Asian economy could be in the offing.
Data wise in Euroland, November’s Industrial Production figures in the bloc will be the only release of note today.
*What to look for around EUR/USD*
In the very near term, the pair would look to the performance of the greenback and the broader risk-appetite trends for direction along with developments from the US-China trade negotiations. In the longer run, the ECB ‘data-dependency’ should grow in significance in light of the apparent slowdown in the region’s fundamentals. This, along with the omnipresent effervescence in the Italian political scenario, the upcoming discussions in the French budget and a potential technical recession in Germany in H2 2018 could somewhat limit the scope for gains in EUR. In addition, the EU Parliamentary elections in May could be a gauge of the current situation around the populism in Europe.
*EUR/USD levels to watch*
At the moment, the pair is up 0.03% at 1.1471 facing the next hurdle at 1.1569 (2019 high Jan.10) seconded by 1.1585 (61.8% Fibo of the September-November drop) and finally 1.1621 (high Oct.16 2018). On the flip side, a breakdown of 1.1447 (10-day SMA) would target 1.1411 (21-day SMA) en route to 1.1306 (2019 low Jan.3). Reported by FXstreet.com 9 minutes ago.
↧
Exane Group Now Live on SimCorp Dimension for Derivatives Business and Ellipsis Asset Management
PRESS RELEASESimCorp, a leading provider of investment management solutions and services to the global financial services industry, today announced that Exane Group and Ellipsis Asset Management (an entity within the group’s asset management arm), have successfully implemented and are now live with SimCorp Dimension. Forming a core system in both entities, SimCorp Dimension will be used for the middle and back office management of listed derivatives and OTC at Exane Derivatives, and in the front and middle office operations at Ellipsis Asset Management. Ellipsis Asset Management is the latest to join over 140 clients worldwide using SimCorp’s front office solutions, from asset managers to pension funds, insurance and banking, as the trend for operational consolidation continues.Based in Paris, Exane Group is an independent investment firm with three successful lines of business (cash equities, derivatives and asset management), spread over a diversified European and global client base. Primed for growth, the firm chose SimCorp Dimension to integrate core investment workflows, in order to scale the business and replace its fragmented and costly IT architecture. The implementation, delivered on time and on budget, is now live in both Exane Derivatives and one of the group’s asset management entities, Ellipsis AM, where SimCorp Dimension plays an essential role in front and middle operations, replacing best of breed front office solutions.With an esteemed track record in active management, specializing in convertible bonds, credit funds and equity overlay, and standing at EUR 2.3 billion AUM, Ellipsis AM is a notable yet nimble player in European bond fund management. The go live has helped the business to increase its agility, with SimCorp Dimension replacing duplicitous systems, streamlining the firm’s architecture and its communication with custodians and fund administrators.
The firm utilizes SimCorp Dimension modules in the front and middle office, from Order Manager (OMS), Asset Manager (portfolio management) and Compliance Manager, to Corporate Actions Manager and Fund Administration Manager. Additionally, with SimCorp’s agnostic Market Data Manager, Ellipsis AM is now connected to its preferred trading platforms, which include TSOX, EMSX and FXall.
A benchmark player in the European derivatives market, and recently voted number one for convertibles in Europe*, Exane Derivatives ensures liquidity through market making of futures, options and convertibles, and now uses SimCorp Dimension in their middle office activities, feeding the back office for listed and OTC derivatives.
Since the implementation of SimCorp Dimension, Exane Derivatives has already established several improvements to the business. The introduction of real-time interfaces for the import of transaction data now provides further accuracy, while access to a wider range of market data, has increased flexibility and responsiveness in its pricing policy. Furthermore, SimCorp Dimension’s intuitive dashboards now provide middle office teams with automated data and workflows, reducing burdensome manual tasks.
*Benoit Catherine, Deputy CEO and Board Member at Exane Group*, commented: “The implementation of SimCorp Dimension for the derivatives business has enabled us to significantly streamline our operations, reduce costs and increase our operational efficiency. With a critical understanding of our business needs and close collaboration throughout the process, SimCorp has delivered this project within both the timeframe and budget we set out with. For us, that assurance has been invaluable.”
*Emmanuelle Bourboulon, Management Board Member and COO at Ellipsis AM,* added: “SimCorp Dimension will enable us to scale for growth by automating our business processes and reducing operational risk. Most importantly, the portfolio managers, middle officers and risk managers are now able to rely on one single real-time position keeping to make their investment decisions, to calculate net asset values and to process pre and post-trade risk controls.”
*Emmanuel Colson, Managing Director at SimCorp Southern Europe*, commented: “We are immensely pleased to have Exane Group using SimCorp Dimension across the two distinctively different business lines; Exane Derivatives and Ellipsis Asset Management. The success of these implementations demonstrates our ability to provide a broad coverage of front to back investment processes in one solution, but also the level of functionality needed to stay competitive and agile, while enabling operational efficiency and cost reduction. This unique approach not only supports scalability of firms such as Exane Group, but also allows them to focus on their core business.”
*Extel European Survey Rankings 2018 (voted by fund managers and commissions weighted)
*
*
*Enquiries regarding this announcement should be addressed to:
*Anders Crillesen, SimCorp Corporate Communications +45 3544 6474 anders.crillesen@simcorp.com
Mittal Shah, SimCorp UK/North America +44 207 397 8072 mittal.shah@simcorp.com
Anne Kermarrec, SimCorp Southern Europe +33 1 55 35 54 63 anne.kermarrec@simcorp.com
*About SimCorp*
SimCorp provides integrated, best-in-class investment management solutions to the world’s leading asset managers, fund managers, asset servicers, pension and insurance funds, wealth managers and sovereign wealth funds. Whether deployed on premise or as an ASP solution, its core system, SimCorp Dimension, supports the entire investment value chain and range of instruments, all based on a market-leading IBOR. SimCorp invests more than 20% of its annual revenue in R&D, helping clients develop their business and stay ahead of ever-changing industry demands. Listed on NASDAQ Copenhagen, SimCorp is a global company, regionally covering all of Europe, North America, and Asia Pacific. For more information, please visit www.simcorp.com.
*About Exane Group*
Founded in 1990, Exane is an investment firm with three lines of business:
Cash equities: Under the brand name Exane BNP Paribas, Exane provides institutional investors with a range of services, such as research, sale and execution on European equities.
Derivatives: Exane Derivatives has built robust franchises in structured products, equity options and convertible bonds.
Asset management: The asset management arm of the Exane Group is embodied by its 2 asset management companies, Exane Asset Management and Ellipsis AM, based respectively on the equity, and credit and convertible bonds universes.
For more information, please visit www.exane.com. Reported by GlobeNewswire 4 minutes ago.
The firm utilizes SimCorp Dimension modules in the front and middle office, from Order Manager (OMS), Asset Manager (portfolio management) and Compliance Manager, to Corporate Actions Manager and Fund Administration Manager. Additionally, with SimCorp’s agnostic Market Data Manager, Ellipsis AM is now connected to its preferred trading platforms, which include TSOX, EMSX and FXall.
A benchmark player in the European derivatives market, and recently voted number one for convertibles in Europe*, Exane Derivatives ensures liquidity through market making of futures, options and convertibles, and now uses SimCorp Dimension in their middle office activities, feeding the back office for listed and OTC derivatives.
Since the implementation of SimCorp Dimension, Exane Derivatives has already established several improvements to the business. The introduction of real-time interfaces for the import of transaction data now provides further accuracy, while access to a wider range of market data, has increased flexibility and responsiveness in its pricing policy. Furthermore, SimCorp Dimension’s intuitive dashboards now provide middle office teams with automated data and workflows, reducing burdensome manual tasks.
*Benoit Catherine, Deputy CEO and Board Member at Exane Group*, commented: “The implementation of SimCorp Dimension for the derivatives business has enabled us to significantly streamline our operations, reduce costs and increase our operational efficiency. With a critical understanding of our business needs and close collaboration throughout the process, SimCorp has delivered this project within both the timeframe and budget we set out with. For us, that assurance has been invaluable.”
*Emmanuelle Bourboulon, Management Board Member and COO at Ellipsis AM,* added: “SimCorp Dimension will enable us to scale for growth by automating our business processes and reducing operational risk. Most importantly, the portfolio managers, middle officers and risk managers are now able to rely on one single real-time position keeping to make their investment decisions, to calculate net asset values and to process pre and post-trade risk controls.”
*Emmanuel Colson, Managing Director at SimCorp Southern Europe*, commented: “We are immensely pleased to have Exane Group using SimCorp Dimension across the two distinctively different business lines; Exane Derivatives and Ellipsis Asset Management. The success of these implementations demonstrates our ability to provide a broad coverage of front to back investment processes in one solution, but also the level of functionality needed to stay competitive and agile, while enabling operational efficiency and cost reduction. This unique approach not only supports scalability of firms such as Exane Group, but also allows them to focus on their core business.”
*Extel European Survey Rankings 2018 (voted by fund managers and commissions weighted)
*
*
*Enquiries regarding this announcement should be addressed to:
*Anders Crillesen, SimCorp Corporate Communications +45 3544 6474 anders.crillesen@simcorp.com
Mittal Shah, SimCorp UK/North America +44 207 397 8072 mittal.shah@simcorp.com
Anne Kermarrec, SimCorp Southern Europe +33 1 55 35 54 63 anne.kermarrec@simcorp.com
*About SimCorp*
SimCorp provides integrated, best-in-class investment management solutions to the world’s leading asset managers, fund managers, asset servicers, pension and insurance funds, wealth managers and sovereign wealth funds. Whether deployed on premise or as an ASP solution, its core system, SimCorp Dimension, supports the entire investment value chain and range of instruments, all based on a market-leading IBOR. SimCorp invests more than 20% of its annual revenue in R&D, helping clients develop their business and stay ahead of ever-changing industry demands. Listed on NASDAQ Copenhagen, SimCorp is a global company, regionally covering all of Europe, North America, and Asia Pacific. For more information, please visit www.simcorp.com.
*About Exane Group*
Founded in 1990, Exane is an investment firm with three lines of business:
Cash equities: Under the brand name Exane BNP Paribas, Exane provides institutional investors with a range of services, such as research, sale and execution on European equities.
Derivatives: Exane Derivatives has built robust franchises in structured products, equity options and convertible bonds.
Asset management: The asset management arm of the Exane Group is embodied by its 2 asset management companies, Exane Asset Management and Ellipsis AM, based respectively on the equity, and credit and convertible bonds universes.
For more information, please visit www.exane.com. Reported by GlobeNewswire 4 minutes ago.
↧
↧
UK TradeMin Fox: Default policy would be for UK to leave with no-deal on March, 29th
The UK Trade Minister Liam Fox is on the wires now, via Reuters, noting that the default policy would be for the UK to leave with no-deal on March, 29^th.
He went on to say that the no-deal Brexit cannot be considered as a National suicide and added that he thinks a no-deal Brexit outcome would damage the economy but is still survivable.
No Brexit at all would lead to rise in populism seen across Europe, Fox said. Reported by FXstreet.com 2 minutes ago.
He went on to say that the no-deal Brexit cannot be considered as a National suicide and added that he thinks a no-deal Brexit outcome would damage the economy but is still survivable.
No Brexit at all would lead to rise in populism seen across Europe, Fox said. Reported by FXstreet.com 2 minutes ago.
↧
The Latest: Road accidents in snowy Bosnia kill 3, hurt 17
BERLIN (AP) — The Latest on heavy snowfall across Europe (all times local):2:10 p.m.Bosnian authorities say three people have died and 17 others have been injured in car and bus crashes on snowy roads across in the Balkan nation.Authorities...
Reported by New Zealand Herald 2 hours ago.
↧
InCloudCounsel Expands Operations in Europe with London Office
The leading end-to-end routine legal document solution provider opens operations in Europe
SAN FRANCISCO (PRWEB) January 14, 2019
InCloudCounsel, a legal technology company offering a global, end-to-end solution for negotiating and managing routine legal work, is pleased to announce the opening of its first European office in London. By establishing dedicated operations in Europe, InCloudCounsel is able to bring its best-in-class solution to significantly more companies in the region. This expansion affirms InCloudCounsel’s commitment to delivering a seamless global solution to its large enterprise clients - the company plans to work with all major legal markets in Europe and open an office in Asia-Pacific by the end of the year. This also creates opportunities for highly experienced corporate lawyers who are yearning for a flexible yet steady work arrangement.
“InCloudCounsel provides clients with the confidence that their recurring, yet important, documents and contracts are being thoroughly managed, so their in-house legal teams can focus on other, more complex work,” says Troy Pospisil, founder and CEO of InCloudCounsel. “Many of our clients have expanded, or plan to expand, into Europe, and by opening an office in London, we will be able to provide these clients with an even more accessible network of highly skilled lawyers to manage their high volume legal work.”
London is often considered a business hub of Europe, making it an ideal location for InCloudCounsel’s regional operations. According to Research and Markets’ Legal Services Global Market Report 2017, the U.K. was the largest European legal market in 2016, accounting for about $45 billion or 7 percent of the global market that year. With its new office located in London, InCloudCounsel will be able to provide European companies with a solution to address the pain points caused by routine legal work.
The expansion is led by Bridget Deiters, Managing Director, U.K. at InCloudCounsel. Prior to InCloudCounsel, Bridget practiced corporate and capital markets law at Kirkland & Ellis and Cravath in London. Bridget holds a J.D. from Georgetown and a B.A. from Yale, and she brings extensive international legal experience to InCloudCounsel.
“We are thrilled to have Bridget join the team,” says Pospisil. “Her experience at leading firms in the European legal market, coupled with her curiosity, empathy, and drive, make her the perfect person to lead our London office.”
InCloudCounsel’s expansion into Europe provides top corporate lawyers with the the freedom to build the practice that best fits their lives. InCloudCounsel works with a select group of some of the world’s top solo and independent practice attorneys who possess deep expertise in specific legal document types. The lawyers working with InCloudCounsel hold an average of nearly 14 years of experience, and most have worked at a top law firm.
To learn more about InCloudCounsel’s ideal solution for negotiating and managing recurring legal work, visit http://www.incloudcounsel.com/.
To learn more about attorney work opportunities with InCloudCounsel, visit http://www.incloudcounsel.com/work/.
About InCloudCounsel
InCloudCounsel is a legal technology company that combines some of the world’s best corporate attorneys with cloud-based software to offer a scalable, end-to-end solution for negotiating and managing routine legal work. InCloudCounsel has helped some of the world’s leading companies effectively streamline their processes, free up resources, and achieve substantial cost savings.
InCloudCounsel is a legal technology company that helps highly experienced corporate lawyers achieve the freedom to practice law without the geographic or time constraints of traditional law firm employment, giving them the opportunity to pursue other passions in life, from starting a business to traveling the world to starting a family.
Media Contact:
Brin Segal
brin.segal@walkersands.com
+1.310.907.6444 Reported by PRWeb 2 hours ago.
SAN FRANCISCO (PRWEB) January 14, 2019
InCloudCounsel, a legal technology company offering a global, end-to-end solution for negotiating and managing routine legal work, is pleased to announce the opening of its first European office in London. By establishing dedicated operations in Europe, InCloudCounsel is able to bring its best-in-class solution to significantly more companies in the region. This expansion affirms InCloudCounsel’s commitment to delivering a seamless global solution to its large enterprise clients - the company plans to work with all major legal markets in Europe and open an office in Asia-Pacific by the end of the year. This also creates opportunities for highly experienced corporate lawyers who are yearning for a flexible yet steady work arrangement.
“InCloudCounsel provides clients with the confidence that their recurring, yet important, documents and contracts are being thoroughly managed, so their in-house legal teams can focus on other, more complex work,” says Troy Pospisil, founder and CEO of InCloudCounsel. “Many of our clients have expanded, or plan to expand, into Europe, and by opening an office in London, we will be able to provide these clients with an even more accessible network of highly skilled lawyers to manage their high volume legal work.”
London is often considered a business hub of Europe, making it an ideal location for InCloudCounsel’s regional operations. According to Research and Markets’ Legal Services Global Market Report 2017, the U.K. was the largest European legal market in 2016, accounting for about $45 billion or 7 percent of the global market that year. With its new office located in London, InCloudCounsel will be able to provide European companies with a solution to address the pain points caused by routine legal work.
The expansion is led by Bridget Deiters, Managing Director, U.K. at InCloudCounsel. Prior to InCloudCounsel, Bridget practiced corporate and capital markets law at Kirkland & Ellis and Cravath in London. Bridget holds a J.D. from Georgetown and a B.A. from Yale, and she brings extensive international legal experience to InCloudCounsel.
“We are thrilled to have Bridget join the team,” says Pospisil. “Her experience at leading firms in the European legal market, coupled with her curiosity, empathy, and drive, make her the perfect person to lead our London office.”
InCloudCounsel’s expansion into Europe provides top corporate lawyers with the the freedom to build the practice that best fits their lives. InCloudCounsel works with a select group of some of the world’s top solo and independent practice attorneys who possess deep expertise in specific legal document types. The lawyers working with InCloudCounsel hold an average of nearly 14 years of experience, and most have worked at a top law firm.
To learn more about InCloudCounsel’s ideal solution for negotiating and managing recurring legal work, visit http://www.incloudcounsel.com/.
To learn more about attorney work opportunities with InCloudCounsel, visit http://www.incloudcounsel.com/work/.
About InCloudCounsel
InCloudCounsel is a legal technology company that combines some of the world’s best corporate attorneys with cloud-based software to offer a scalable, end-to-end solution for negotiating and managing routine legal work. InCloudCounsel has helped some of the world’s leading companies effectively streamline their processes, free up resources, and achieve substantial cost savings.
InCloudCounsel is a legal technology company that helps highly experienced corporate lawyers achieve the freedom to practice law without the geographic or time constraints of traditional law firm employment, giving them the opportunity to pursue other passions in life, from starting a business to traveling the world to starting a family.
Media Contact:
Brin Segal
brin.segal@walkersands.com
+1.310.907.6444 Reported by PRWeb 2 hours ago.
↧
12 ReTech to Acquire Red Wire Group, LLC to Increase the Manufacturing Capability and Revenue of its Emotion Fashion Group Subsidiary
Las Vegas, NV & Hong Kong, Jan. 14, 2019 (GLOBE NEWSWIRE) -- 12 ReTech Corporation (OTCQB: RETC) announced today that it has signed a definitive Exchange of Equity Agreement to acquire Salt Lake City, Utah based Red Wire Group, LLC (“Red Wire”) in a stock for stock transaction. Closing is scheduled to occur before the end of this month.
Red Wire Group, LLC (“Red Wire”) is a profitable and efficient contract “Cut and Sew” manufacturer generating significant revenue and is located less than 100 yards from the Company’s Emotion Fashion Group (“EFG”) facility. Red Wire Group has maxed out its own existing facilities capacity and can benefit from the excess capacity that EFG currently possesses.
Angelo Ponzetta, 12 ReTech’s CEO stated, “We believe that Red Wire is very synergistic to our current EFG operation. In addition to the revenue and profits that Red Wire brings to the group we add efficiency and expertise to continue to drive down our production costs that began with our relocation of EFG from Los Angeles to Salt Lake City. This extra capacity and efficiency will allow Red Wire to take on many more jobs that should catapult its revenue from its current $650,000 to three to four times that annually, while increasing our margins.”
Hub Blanchett, President of EFG stated, “Being acquired by 12 ReTech was just the catalyst for future acquisitions. I am thrilled to team up with Red Wire. Their production team is outstanding and will allow our team to focus on revenue growth and delivery fulfillment.”.
Angelo Ponzetta, 12 ReTech’s CEO continued, “We have been working on this acquisition throughout the holiday season and while we executed non-binding Letters of Intent we decided to wait until the signing of the Exchange Agreement to announce this news as our past experience with acquisitions has taught us that Murphy’s law typically applies at the signed Letter of Intent stage”.
Greg Haehl, Managing Member of Red Wire commented, “I am excited to become part of 12 ReTech team. Being a technology expert myself, I have seen what they are doing to help retailers improve themselves. The technology that is available at 12 ReTech is very exciting and I plan to lend my own expertise to their efforts. At the same time, Red Wire’s capabilities will help EFG’s own manufacturing floor operations and their extra capacity will allow us to substantially grow our own business.” He continued, “I have seen first-hand the commitment and assistance the whole 12 ReTech Team brings to every acquisition and this strongly influenced our decision to be acquired.”
Angelo Ponzetta added, “We have been informed that due to our current stock price OTC Markets intends to shortly remove us from their QB group. They have indicated that once our stock reaches and maintains the mandatory $0.01 threshold price for 10 days it’s a simple matter to regain the QB status. Historically, the QB designation hasn’t yet really benefitted our investors but the reporting requirements which we maintain as a QB stock will continue to be maintained. We are optimistic that with the important acquisitions we are closing, the investing public will view our Company more favorably and our stock should respond accordingly, allowing us to be re-certified as a QB stock.
Angelo Ponzetta finished, “The target date for the completion of this acquisition is on or about January 23, 2019. The closing of this transaction is still subject to completion of due diligence and a few other details. Red Wire acquisition coupled with EFG acquisition provides us with a *strong operating base for additional acquisitions we hope to announce soon. *
*About Red Wire Group, LLC*
Red Wire Group's primary goal as an apparel and clothing manufacturer is to capture your vision and translate that into a high quality sewn product. We have extremely skilled pattern-makers, graphic designers and production workers who work together to produce the top clothing and sewn goods in the market.
WHAT DRIVES US
Red Wire Group is a group of designers and makers with a unified purpose. Seeing our client's products be developed is inspiring to us and the products are inspiring to others. We thrive on creativity and feed off of the creativity of our customers and clients. Our happiest moments are the reveals whether it is during a fit test or the presentation of a newly designed logo. These moments are what we work for to make them amazing and memorable for our customers so that momentum can continue forward and reach all the customers that purchase our final products.
THE RED WIRE GROUP CLOTHING FACTORY
Our factory is located near 33rd South and West Temple in Salt Lake City, Utah. We are working to offer a high-tech clothing factory to apparel brands located in Utah and the surrounding states. A place where brand owners can visit and watch their clothing being made.
*About 12 ReTech Corporation:*
At our core, we are a software company whose technology allows retailers to combat the dual threats of Walmart and Amazon — both online and in physical stores. Our microbrand rollup acquisition strategy allows us to demonstrate the effectiveness of our software, devise and test new products, while providing shareholder value through immediate revenue and earnings growth. The Company operates through our subsidiaries on three continents: 12 Hong Kong, Ltd., 12 Japan, Ltd., 12 Europe A.G., 12 Retail Corporation (and its subsidiaries in North America, including Emotion Fashion Group, Inc.). For more information please visit our website at www.12ReTech.com.
12 ReTech Corporation is publicly listed on the OTCQB Markets under the symbol RETC.
*Safe Harbor:* This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate,""anticipate,""expect,""believe," and similar expressions are intended to be forward-looking statements.
*Investors Relations Contacts:*
Mark Gilbert
Magellan FIN, LLC
mgilbert@magellanfin.com
317-361-2392 (USA)
Corporate Headquarters
investors@12ReTech.com Reported by GlobeNewswire 2 hours ago.
Red Wire Group, LLC (“Red Wire”) is a profitable and efficient contract “Cut and Sew” manufacturer generating significant revenue and is located less than 100 yards from the Company’s Emotion Fashion Group (“EFG”) facility. Red Wire Group has maxed out its own existing facilities capacity and can benefit from the excess capacity that EFG currently possesses.
Angelo Ponzetta, 12 ReTech’s CEO stated, “We believe that Red Wire is very synergistic to our current EFG operation. In addition to the revenue and profits that Red Wire brings to the group we add efficiency and expertise to continue to drive down our production costs that began with our relocation of EFG from Los Angeles to Salt Lake City. This extra capacity and efficiency will allow Red Wire to take on many more jobs that should catapult its revenue from its current $650,000 to three to four times that annually, while increasing our margins.”
Hub Blanchett, President of EFG stated, “Being acquired by 12 ReTech was just the catalyst for future acquisitions. I am thrilled to team up with Red Wire. Their production team is outstanding and will allow our team to focus on revenue growth and delivery fulfillment.”.
Angelo Ponzetta, 12 ReTech’s CEO continued, “We have been working on this acquisition throughout the holiday season and while we executed non-binding Letters of Intent we decided to wait until the signing of the Exchange Agreement to announce this news as our past experience with acquisitions has taught us that Murphy’s law typically applies at the signed Letter of Intent stage”.
Greg Haehl, Managing Member of Red Wire commented, “I am excited to become part of 12 ReTech team. Being a technology expert myself, I have seen what they are doing to help retailers improve themselves. The technology that is available at 12 ReTech is very exciting and I plan to lend my own expertise to their efforts. At the same time, Red Wire’s capabilities will help EFG’s own manufacturing floor operations and their extra capacity will allow us to substantially grow our own business.” He continued, “I have seen first-hand the commitment and assistance the whole 12 ReTech Team brings to every acquisition and this strongly influenced our decision to be acquired.”
Angelo Ponzetta added, “We have been informed that due to our current stock price OTC Markets intends to shortly remove us from their QB group. They have indicated that once our stock reaches and maintains the mandatory $0.01 threshold price for 10 days it’s a simple matter to regain the QB status. Historically, the QB designation hasn’t yet really benefitted our investors but the reporting requirements which we maintain as a QB stock will continue to be maintained. We are optimistic that with the important acquisitions we are closing, the investing public will view our Company more favorably and our stock should respond accordingly, allowing us to be re-certified as a QB stock.
Angelo Ponzetta finished, “The target date for the completion of this acquisition is on or about January 23, 2019. The closing of this transaction is still subject to completion of due diligence and a few other details. Red Wire acquisition coupled with EFG acquisition provides us with a *strong operating base for additional acquisitions we hope to announce soon. *
*About Red Wire Group, LLC*
Red Wire Group's primary goal as an apparel and clothing manufacturer is to capture your vision and translate that into a high quality sewn product. We have extremely skilled pattern-makers, graphic designers and production workers who work together to produce the top clothing and sewn goods in the market.
WHAT DRIVES US
Red Wire Group is a group of designers and makers with a unified purpose. Seeing our client's products be developed is inspiring to us and the products are inspiring to others. We thrive on creativity and feed off of the creativity of our customers and clients. Our happiest moments are the reveals whether it is during a fit test or the presentation of a newly designed logo. These moments are what we work for to make them amazing and memorable for our customers so that momentum can continue forward and reach all the customers that purchase our final products.
THE RED WIRE GROUP CLOTHING FACTORY
Our factory is located near 33rd South and West Temple in Salt Lake City, Utah. We are working to offer a high-tech clothing factory to apparel brands located in Utah and the surrounding states. A place where brand owners can visit and watch their clothing being made.
*About 12 ReTech Corporation:*
At our core, we are a software company whose technology allows retailers to combat the dual threats of Walmart and Amazon — both online and in physical stores. Our microbrand rollup acquisition strategy allows us to demonstrate the effectiveness of our software, devise and test new products, while providing shareholder value through immediate revenue and earnings growth. The Company operates through our subsidiaries on three continents: 12 Hong Kong, Ltd., 12 Japan, Ltd., 12 Europe A.G., 12 Retail Corporation (and its subsidiaries in North America, including Emotion Fashion Group, Inc.). For more information please visit our website at www.12ReTech.com.
12 ReTech Corporation is publicly listed on the OTCQB Markets under the symbol RETC.
*Safe Harbor:* This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate,""anticipate,""expect,""believe," and similar expressions are intended to be forward-looking statements.
*Investors Relations Contacts:*
Mark Gilbert
Magellan FIN, LLC
mgilbert@magellanfin.com
317-361-2392 (USA)
Corporate Headquarters
investors@12ReTech.com Reported by GlobeNewswire 2 hours ago.
↧
↧
LastPass Launches STEM Scholarship Program to Build Next Generation of Tech Leaders
High School Seniors, College Students Eligible for Resources Supporting STEM Education
BOSTON, Jan. 14, 2019 (GLOBE NEWSWIRE) -- LastPass by LogMeIn, a leader in password management, today announced the launch of the LastPass STEM Scholarship Program, which aims to support students pursuing an education in science, technology, engineering or math (STEM) fields. Through the new program, LastPass will award one graduating high school or current college student $10,000 for tuition and $2,000 for books.The scholarship is being supported in part by LogMeIn’s Corporate Social Responsibility program, Mission Possible, which supports education and youth programs increasing access to K-12 education, closing the diversity and achievement gap in tech, and providing STEM programs and developing digital skills.
LastPass STEM Scholarship Program applicants must meet the following requirements:
· Students must be high school seniors or currently enrolled in a college or university in the United States.
· Student must be majoring in or planning to major in a STEM field.
· Current GPA must be above a 3.0.
· Applicants must first submit an essay, and those who proceed to the second round will be notified via email to submit a video.
“Our LastPass customers have given us so much over the past ten years – their time, feedback, and trust – that we’ve been inspired to give back by supporting the next generation of tech leaders,” said John Bennett, General Manager, Identity and Access Business at LogMeIn. “A STEM education is critical to helping close the skills gap facing the constantly evolving nature of the security industry. This scholarship is part of our ongoing commitment to improving the future of cybersecurity. And who knows – someday the winner could be a LastPass developer at LogMeIn.”
The application submission deadline is *April 30, 2019*, and the winner will be announced in July 2019. For additional information and to apply, please visit LastPass.com/Scholarship.
To learn more about Mission Possible and LogMeIn’s efforts to support STEM education in communities across the country, click here.
*About LastPass*
LastPass is an award-winning password manager helping millions organize and protect their online lives, at home and at work. For businesses of all sizes, LastPass provides secure password storage and centralized admin oversight to reduce the risk of data breaches and remove password obstacles for employees. With customizable policies, secure password sharing, and comprehensive user management, LastPass gives IT the tools to strengthen password hygiene across the organization. For more information, visit https://lastpass.com.
LastPass is a trademark of LogMeIn in the U.S. and other countries.
*About LogMeIn, Inc.*
LogMeIn, Inc. (Nasdaq: LOGM) simplifies how people connect with each other and the world around them to drive meaningful interactions, deepen relationships, and create better outcomes for individuals and businesses. One of the world’s top 10 public SaaS companies, and a market leader in communication & conferencing, identity & access, and customer engagement & support solutions, LogMeIn has millions of customers spanning virtually every country across the globe. LogMeIn is headquartered in Boston with additional locations in North and South America, Europe, Asia and Australia.
*Media Contact:*
Lauren Van Dam
press@lastpass.com
781-897-1328 Reported by GlobeNewswire 2 hours ago.
BOSTON, Jan. 14, 2019 (GLOBE NEWSWIRE) -- LastPass by LogMeIn, a leader in password management, today announced the launch of the LastPass STEM Scholarship Program, which aims to support students pursuing an education in science, technology, engineering or math (STEM) fields. Through the new program, LastPass will award one graduating high school or current college student $10,000 for tuition and $2,000 for books.The scholarship is being supported in part by LogMeIn’s Corporate Social Responsibility program, Mission Possible, which supports education and youth programs increasing access to K-12 education, closing the diversity and achievement gap in tech, and providing STEM programs and developing digital skills.
LastPass STEM Scholarship Program applicants must meet the following requirements:
· Students must be high school seniors or currently enrolled in a college or university in the United States.
· Student must be majoring in or planning to major in a STEM field.
· Current GPA must be above a 3.0.
· Applicants must first submit an essay, and those who proceed to the second round will be notified via email to submit a video.
“Our LastPass customers have given us so much over the past ten years – their time, feedback, and trust – that we’ve been inspired to give back by supporting the next generation of tech leaders,” said John Bennett, General Manager, Identity and Access Business at LogMeIn. “A STEM education is critical to helping close the skills gap facing the constantly evolving nature of the security industry. This scholarship is part of our ongoing commitment to improving the future of cybersecurity. And who knows – someday the winner could be a LastPass developer at LogMeIn.”
The application submission deadline is *April 30, 2019*, and the winner will be announced in July 2019. For additional information and to apply, please visit LastPass.com/Scholarship.
To learn more about Mission Possible and LogMeIn’s efforts to support STEM education in communities across the country, click here.
*About LastPass*
LastPass is an award-winning password manager helping millions organize and protect their online lives, at home and at work. For businesses of all sizes, LastPass provides secure password storage and centralized admin oversight to reduce the risk of data breaches and remove password obstacles for employees. With customizable policies, secure password sharing, and comprehensive user management, LastPass gives IT the tools to strengthen password hygiene across the organization. For more information, visit https://lastpass.com.
LastPass is a trademark of LogMeIn in the U.S. and other countries.
*About LogMeIn, Inc.*
LogMeIn, Inc. (Nasdaq: LOGM) simplifies how people connect with each other and the world around them to drive meaningful interactions, deepen relationships, and create better outcomes for individuals and businesses. One of the world’s top 10 public SaaS companies, and a market leader in communication & conferencing, identity & access, and customer engagement & support solutions, LogMeIn has millions of customers spanning virtually every country across the globe. LogMeIn is headquartered in Boston with additional locations in North and South America, Europe, Asia and Australia.
*Media Contact:*
Lauren Van Dam
press@lastpass.com
781-897-1328 Reported by GlobeNewswire 2 hours ago.
↧
Patricia Nyberg appointed member of the Board of Directors of Telko
Aspo Plc
Stock exchange release
January 14, 2019 at 4 p.m.*PATRICIA NYBERG APPOINTED MEMBER OF THE BOARD OF DIRECTORS OF TELKO*
*Patricia Nyberg *(M.Sc. (Econ), MBA (IMD), born 1985), has been appointed member of the Board of Directors of Telko Ltd, part of Aspo Group, starting from January 1, 2019. Patricia Nyberg is working as Business Manager at Tessin Nordic AB and is the Chairman of the Board of Directors of Havsudden Oy.
"Patricia Nyberg will start as a member of the Board of Directors of Telko, Aspo's largest and most international business. Patricia's experience in international trade and her solid expertise in financing are a perfect match for Telko's current strong development phase," says Aki Ojanen, Chairman of the Board of Directors of Telko.
Telko has grown strongly and expanded its operating area, and has currently subsidiaries in 18 countries. The increase in net sales and profitability is based on its long-term expansion in Russia, Ukraine and other CIS countries. Most recently, the company has expanded to the emerging markets of Central Europe. The company's positive profitability development is also based on its improved profitability in the western markets and its significantly expanded customer base, for example in Finland, Scandinavia and Poland.
*Anders Dahlblom*, Managing Director of Paroc Group, has stated that due to his new tasks he is unable to continue as a member of the Board of Directors after March 1, 2019.* Elina Piispanen*, Chief Transformation Officer at Sanoma Media Finland, and Ralf Holmlund *will continue as members of the Board of Directors*, and* Aki Ojanen*, CEO of Aspo Plc, will continue as the Chairman. ASPO Plc
Aki Ojanen
CEO
Further information:
Aki Ojanen, CEO of Aspo Plc and Chairman of the Board of Directors of Telko,
tel. +358 9 521 4010, +358 400 106 592, aki.ojanen@aspo.comDistribution:
Nasdaq Helsinki
Key media
www.aspo.com*Aspo* is a conglomerate that owns and develops business operations in Northern Europe and growth markets, focusing on demanding B2B customers. The aim of our strong corporate brands - ESL Shipping, Leipurin, Telko and Kauko - is to be the market leaders in their sectors. They are responsible for their own operations, customer relationships, and their development. Together they generate Aspo's goodwill. Reported by GlobeNewswire 2 hours ago.
Stock exchange release
January 14, 2019 at 4 p.m.*PATRICIA NYBERG APPOINTED MEMBER OF THE BOARD OF DIRECTORS OF TELKO*
*Patricia Nyberg *(M.Sc. (Econ), MBA (IMD), born 1985), has been appointed member of the Board of Directors of Telko Ltd, part of Aspo Group, starting from January 1, 2019. Patricia Nyberg is working as Business Manager at Tessin Nordic AB and is the Chairman of the Board of Directors of Havsudden Oy.
"Patricia Nyberg will start as a member of the Board of Directors of Telko, Aspo's largest and most international business. Patricia's experience in international trade and her solid expertise in financing are a perfect match for Telko's current strong development phase," says Aki Ojanen, Chairman of the Board of Directors of Telko.
Telko has grown strongly and expanded its operating area, and has currently subsidiaries in 18 countries. The increase in net sales and profitability is based on its long-term expansion in Russia, Ukraine and other CIS countries. Most recently, the company has expanded to the emerging markets of Central Europe. The company's positive profitability development is also based on its improved profitability in the western markets and its significantly expanded customer base, for example in Finland, Scandinavia and Poland.
*Anders Dahlblom*, Managing Director of Paroc Group, has stated that due to his new tasks he is unable to continue as a member of the Board of Directors after March 1, 2019.* Elina Piispanen*, Chief Transformation Officer at Sanoma Media Finland, and Ralf Holmlund *will continue as members of the Board of Directors*, and* Aki Ojanen*, CEO of Aspo Plc, will continue as the Chairman. ASPO Plc
Aki Ojanen
CEO
Further information:
Aki Ojanen, CEO of Aspo Plc and Chairman of the Board of Directors of Telko,
tel. +358 9 521 4010, +358 400 106 592, aki.ojanen@aspo.comDistribution:
Nasdaq Helsinki
Key media
www.aspo.com*Aspo* is a conglomerate that owns and develops business operations in Northern Europe and growth markets, focusing on demanding B2B customers. The aim of our strong corporate brands - ESL Shipping, Leipurin, Telko and Kauko - is to be the market leaders in their sectors. They are responsible for their own operations, customer relationships, and their development. Together they generate Aspo's goodwill. Reported by GlobeNewswire 2 hours ago.
↧
Norwegian Cruise Line Holdings Ltd. Announces Opening of Second School With Proceeds From Hope Starts Here Hurricane Relief Campaign
Morne Prosper Pre and Primary Schools Re-Open their Doors in Dominica
MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands, today announced the re-opening of the Morne Prosper Pre and Primary Schools in Morne Prosper Village, Dominica, the second school to benefit from the company’s Hope Starts Here hurricane relief campaign.Together with All Hands and Hearts, the company raised over $2.5 million dollars to deliver early relief response and rebuild safe, resilient schools in the Caribbean communities impacted by Hurricanes Irma and Maria. A portion of the proceeds was used to rebuild the pre and primary schools in Morne Prosper Village, which suffered extensive damage from Hurricane Maria. For the primary school, two classrooms that were completely destroyed were rebuilt while new, much-needed kitchen and water, sanitation and hygiene (WASH) facilities were also constructed for the school. The entire pre-school was also rebuilt with the addition of a new playground.
On January 10, officials from Norwegian Cruise Line Holdings and All Hands and Hearts along with local representatives from Dominica attended the grand opening celebration of the pre-Kindergarten through sixth grade school, which will open its doors to teachers and students today.
“We are thrilled to celebrate the opening of the second school in the Caribbean that has benefited from our Hope Starts Here hurricane relief campaign in partnership with All Hands and Hearts,” said Frank Del Rio, president and chief executive officer of Norwegian Cruise Line Holdings Ltd. “We are incredibly thankful for all those who have brought lasting hope to children, families and the Dominica community by contributing to the re-opening of the Morne Prosper Pre and Primary Schools.”
“We’re grateful for partners like Norwegian Cruise Line Holdings who support our response and recovery efforts,” said David Campbell, Co-Founder and Chairman of All Hands and Hearts. “At the center of our work are Build Back Better techniques to make schools, like Morne Prosper, resistant against future natural disasters. Working closely with the Ministry of Education, other NGOs, the schools and local communities, this essential work will create much safer, resilient learning environments, and also serve as evacuation shelters for surrounding communities.”
The Hope Starts Here hurricane relief program launched in late September 2017, when the company partnered with relief organization All Hands and Hearts to help provide immediate relief in Key West and reconstruct schools and critical infrastructure in affected islands in the Caribbean including St. Thomas, St. Maarten and Tortola. It has been the largest fundraising campaign in the company’s history. Within 90 days of the launch, Hope Starts Here reached its goal of raising $2.5 million to assist All Hands and Hearts. The program received more than $1.25 million in donations from the company’s valued team members, loyal guests, travel partners and business partners, which Norwegian Cruise Line Holdings Ltd. matched.
*About Norwegian Cruise Line Holdings Ltd.*
Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) is a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 26 ships with approximately 54,400 berths, these brands offer itineraries to more than 450 destinations worldwide. The Company will introduce ten additional ships through 2027.
Norwegian Cruise Line is the innovator in cruise travel with a 52-year history of breaking the boundaries of traditional cruising. Most notably, Norwegian revolutionized the cruise industry by offering guests the freedom and flexibility to design their ideal cruise vacation on their schedule with no set dining times, a variety of entertainment options and no formal dress codes. Today, Norwegian invites guests to enjoy a relaxed, resort- style cruise vacation on some of the newest and most contemporary ships at sea with a wide variety of accommodations options, including The Haven by Norwegian®, a luxury enclave with suites, private pool and dining, concierge service and personal butlers. Norwegian Cruise Line sails around the globe, offering guests the freedom and flexibility to explore the world on their own time and experience up to 27 dining options, award-winning entertainment, superior guest service and more across all of the brand’s 16 ships.
Oceania Cruises is the world’s leading culinary- and destination-focused cruise line. The line’s six intimate and luxurious ships which carry only 684 or 1,250 guests offer an unrivaled vacation experience featuring the finest cuisine at sea and destination-rich itineraries that span the globe. Expertly crafted voyages aboard designer-inspired, intimate ships call on more than 450 ports across Europe, Alaska, Asia, Africa, Australia, New Zealand, New England-Canada, Bermuda, the Caribbean, Panama Canal, Tahiti and the South Pacific and epic Around The World Voyages that range from 180 to 200 days.
Regent Seven Seas Cruises is the world’s most inclusive luxury experience with a modern, five-ship fleet that visits more than 450 iconic and immersive destinations around the world. The cruise line’s fares include all-suite accommodations, round-trip business-class air on intercontinental flights from U.S. and Canada, the largest collection of free, unlimited shore excursions, unlimited internet access, highly personalized service, exquisite cuisine, fine wines and spirits, prepaid gratuities, ground transfers and one-night, pre-cruise hotel package for guests staying in Concierge-level suites and higher. Its spacious and intimate ships have a capacity of up to 750 guests. Seven Seas Mariner’s 2018 dry-dock refurbishment concluded the line’s $125 million refurbishment program to elevate the fleet’s elegance to the standard set by Seven Seas Explorer, the most luxurious ship ever built. In early 2020, Regent will perfect luxury with the launch of Seven Seas Splendor.
*About All Hands and Hearts*
All Hands and Hearts effectively and efficiently addresses the immediate and long-term needs of communities impacted by natural disasters. By listening to local people, and deploying our unique model of engaging volunteers to enable direct impact, we rebuild safe, resilient schools, homes and other community infrastructure.
*Investor Relations Contact:* *Media Contact:*
Andrea DeMarco Christine Da Silva
(305) 468-2339 (305) 436-4713
InvestorRelations@nclcorp.com Publicrelations@ncl.com
Reported by GlobeNewswire 2 hours ago.
MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands, today announced the re-opening of the Morne Prosper Pre and Primary Schools in Morne Prosper Village, Dominica, the second school to benefit from the company’s Hope Starts Here hurricane relief campaign.Together with All Hands and Hearts, the company raised over $2.5 million dollars to deliver early relief response and rebuild safe, resilient schools in the Caribbean communities impacted by Hurricanes Irma and Maria. A portion of the proceeds was used to rebuild the pre and primary schools in Morne Prosper Village, which suffered extensive damage from Hurricane Maria. For the primary school, two classrooms that were completely destroyed were rebuilt while new, much-needed kitchen and water, sanitation and hygiene (WASH) facilities were also constructed for the school. The entire pre-school was also rebuilt with the addition of a new playground.
On January 10, officials from Norwegian Cruise Line Holdings and All Hands and Hearts along with local representatives from Dominica attended the grand opening celebration of the pre-Kindergarten through sixth grade school, which will open its doors to teachers and students today.
“We are thrilled to celebrate the opening of the second school in the Caribbean that has benefited from our Hope Starts Here hurricane relief campaign in partnership with All Hands and Hearts,” said Frank Del Rio, president and chief executive officer of Norwegian Cruise Line Holdings Ltd. “We are incredibly thankful for all those who have brought lasting hope to children, families and the Dominica community by contributing to the re-opening of the Morne Prosper Pre and Primary Schools.”
“We’re grateful for partners like Norwegian Cruise Line Holdings who support our response and recovery efforts,” said David Campbell, Co-Founder and Chairman of All Hands and Hearts. “At the center of our work are Build Back Better techniques to make schools, like Morne Prosper, resistant against future natural disasters. Working closely with the Ministry of Education, other NGOs, the schools and local communities, this essential work will create much safer, resilient learning environments, and also serve as evacuation shelters for surrounding communities.”
The Hope Starts Here hurricane relief program launched in late September 2017, when the company partnered with relief organization All Hands and Hearts to help provide immediate relief in Key West and reconstruct schools and critical infrastructure in affected islands in the Caribbean including St. Thomas, St. Maarten and Tortola. It has been the largest fundraising campaign in the company’s history. Within 90 days of the launch, Hope Starts Here reached its goal of raising $2.5 million to assist All Hands and Hearts. The program received more than $1.25 million in donations from the company’s valued team members, loyal guests, travel partners and business partners, which Norwegian Cruise Line Holdings Ltd. matched.
*About Norwegian Cruise Line Holdings Ltd.*
Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) is a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 26 ships with approximately 54,400 berths, these brands offer itineraries to more than 450 destinations worldwide. The Company will introduce ten additional ships through 2027.
Norwegian Cruise Line is the innovator in cruise travel with a 52-year history of breaking the boundaries of traditional cruising. Most notably, Norwegian revolutionized the cruise industry by offering guests the freedom and flexibility to design their ideal cruise vacation on their schedule with no set dining times, a variety of entertainment options and no formal dress codes. Today, Norwegian invites guests to enjoy a relaxed, resort- style cruise vacation on some of the newest and most contemporary ships at sea with a wide variety of accommodations options, including The Haven by Norwegian®, a luxury enclave with suites, private pool and dining, concierge service and personal butlers. Norwegian Cruise Line sails around the globe, offering guests the freedom and flexibility to explore the world on their own time and experience up to 27 dining options, award-winning entertainment, superior guest service and more across all of the brand’s 16 ships.
Oceania Cruises is the world’s leading culinary- and destination-focused cruise line. The line’s six intimate and luxurious ships which carry only 684 or 1,250 guests offer an unrivaled vacation experience featuring the finest cuisine at sea and destination-rich itineraries that span the globe. Expertly crafted voyages aboard designer-inspired, intimate ships call on more than 450 ports across Europe, Alaska, Asia, Africa, Australia, New Zealand, New England-Canada, Bermuda, the Caribbean, Panama Canal, Tahiti and the South Pacific and epic Around The World Voyages that range from 180 to 200 days.
Regent Seven Seas Cruises is the world’s most inclusive luxury experience with a modern, five-ship fleet that visits more than 450 iconic and immersive destinations around the world. The cruise line’s fares include all-suite accommodations, round-trip business-class air on intercontinental flights from U.S. and Canada, the largest collection of free, unlimited shore excursions, unlimited internet access, highly personalized service, exquisite cuisine, fine wines and spirits, prepaid gratuities, ground transfers and one-night, pre-cruise hotel package for guests staying in Concierge-level suites and higher. Its spacious and intimate ships have a capacity of up to 750 guests. Seven Seas Mariner’s 2018 dry-dock refurbishment concluded the line’s $125 million refurbishment program to elevate the fleet’s elegance to the standard set by Seven Seas Explorer, the most luxurious ship ever built. In early 2020, Regent will perfect luxury with the launch of Seven Seas Splendor.
*About All Hands and Hearts*
All Hands and Hearts effectively and efficiently addresses the immediate and long-term needs of communities impacted by natural disasters. By listening to local people, and deploying our unique model of engaging volunteers to enable direct impact, we rebuild safe, resilient schools, homes and other community infrastructure.
*Investor Relations Contact:* *Media Contact:*
Andrea DeMarco Christine Da Silva
(305) 468-2339 (305) 436-4713
InvestorRelations@nclcorp.com Publicrelations@ncl.com
Reported by GlobeNewswire 2 hours ago.
↧
More Pages to Explore .....
